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Abstract 
Tumors with histological features of pilocytic astrocytoma (PA), but with increased mitotic 
activity and additional high-grade features (particularly microvascular proliferation and 
palisading necrosis) have often been designated anaplastic pilocytic astrocytomas. The 
status of these tumors as a separate entity has not yet been conclusively demonstrated and 
molecular features have only been partially characterized. We performed DNA methylation 
profiling of 102 histologically defined anaplastic pilocytic astrocytomas. T-distributed 
stochastic neighbor embedding (t-SNE) and hierarchical clustering analysis of these 102 
cases against 158 reference cases from 12 glioma reference classes revealed that a subset 
of 83 of these tumors share a common DNA methylation profile that is distinct from the 
reference classes. These 83 tumors were thus denominated DNA methylation class 
anaplastic astrocytoma with piloid features (MC AAP). The 19 remaining tumors were 
distributed amongst the previous reference classes, with additional testing confirming the 
molecular diagnosis in most cases. Median age of patients with MC AAP was 41.5 years. 
The most frequent localization was the posterior fossa (74%). Deletions of CDKN2A/B 
(66/83, 80%), MAPK pathway gene alterations (49/65, 75%, most frequently affecting NF1, 
followed by BRAF and FGFR1) and mutations of ATRX or loss of ATRX expression (33/74, 
45%) were the most common molecular alterations. All tumors were IDH1/2 wildtype. The 
MGMT promoter was methylated in 38/83 tumors (45%). Outcome analysis confirmed an 
unfavorable clinical course in comparison to PA, but better than IDH wildtype glioblastoma 
(GBM). In conclusion, we show that a subset of histologically defined anaplastic pilocytic 
astrocytomas forms a separate DNA methylation cluster, harbors recurrent alterations in 
MAPK pathway genes in combination with alterations of CDKN2A/B and ATRX, affects 
patients who are on average older than those diagnosed with PA and has an intermediate 
clinical outcome. 
Key words 
anaplastic pilocytic astrocytoma; pilocytic astrocytoma with anaplasia; methylation profile 
based classification; panel sequencing; ATRX; BRAF; NF1; FGFR1; MGMT; CDKN2A/B; 
molecular characterization; DNA copy number alterations 
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Introduction 
PA accounts for approximately 5% of gliomas across all age groups and for approximately 
25% of all brain tumors encountered in pediatric neurosurgical practice [8, 50], thereby 
representing the most common primary brain tumor in patients of 0 to 19 years of age. In 
contrast, the majority of gliomas in adults are either diffuse gliomas with IDH1 mutation 
(either 1p19q co-deleted or 1p19q intact) or highly malignant GBMs [54]. Where gross total 
resection is feasible, clinical outcome of PA is usually favorable with 10 year overall survival 
rates of around 95% [8, 9, 13, 44]. The vast majority of PAs harbor single genetic alterations 
in genes encoding proteins of the mitogen-activated protein kinase (MAPK) pathway, with the 
most frequent findings being fusions of BRAF with KIAA1549 or rarely other genes, BRAF 
V600E point mutation, or alterations of NF1, FGFR1 or NTRK family genes [24]. Different 
localizations of PA are associated with different frequencies of molecular alterations, with 
posterior fossa tumors harboring a BRAF fusion in up to 80-90% of cases and supratentorial 
lesions showing this alteration in only about 60% of cases [20, 21]. Of further interest is the 
reported age association of BRAF fusions that seem to be less frequent in the adult 
population (e.g. 30% of patients of 31-40 years and 7% of patients older than 40 years of 
age) [16, 21]. To date, BRAF fusions are considered a molecular hallmark of WHO grade I 
PA with a typically favorable outcome [17, 20, 46]. Rare cases of PA, particularly in older 
patients, can have a more aggressive clinical behavior [3, 5, 43, 44, 50, 57]. The tumors of 
these patients may show anaplastic histological features including increased nuclear atypia, 
increased mitotic activity, prominent endothelial proliferation and/or palisading necrosis and 
have been discussed to represent a separate entity or subentity [44]. In the WHO 
classification 2016, this glioma subgroup is designated pilocytic astrocytoma with anaplasia. 
The identification of this particular subset of more aggressively behaving tumors is 
challenging, as the histological features described in the WHO classification do not exclude 
the diagnosis of conventional PA WHO grade I [8, 44], while histological overlap with 
pleomorphic xanthoastrocytoma/anaplastic pleomorphic xanthoastrocytoma and GBM is also 
evident. Moreover, according to the WHO classification, grading and nomenclature of 
pilocytic astrocytoma with anaplasia are still to be conclusively defined [29]. One study on the 
molecular characterization of clinically aggressive/recurrent or histologically defined 
anaplastic pilocytic astrocytomas revealed a heterozygous PTEN/10q loss in 6 of 19 (32%) 
and a homozygous CDKN2A/B deletion in 3 of 15 (20%) cases with BRAF fusions identified 
in 63% of cerebellar lesions [43]. A different study observed an association with 
neurofibromatosis type I in 28% of histologically defined anaplastic pilocytic astrocytomas 
[15]. Nevertheless, more comprehensive approaches are necessary to establish the 
characteristic molecular profile of this tumor class. 
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Recently, DNA methylation profiling has become an important adjunct tool for tumor 
classification and identification of molecular subclasses [18, 31, 34, 35, 45, 48, 51, 52]. To 
molecularly characterize histologically defined anaplastic pilocytic astrocytomas, we 
analyzed a retrospective series of 102 cases with histological features of this putative entity 
by DNA methylation profiling, DNA copy number analysis, next generation gene panel 
sequencing as well as by histological characterization and correlated these data with clinical 
information. Herein, we report that a major subset (83/102, 81%) of these tumors show a 
common DNA methylation profile, harbor frequent MAPK pathway gene alterations and have 
additional molecular and clinical features that clearly distinguish them from WHO grade I PAs 
as well as from other adult diffuse gliomas. 
Materials and Methods 
Tissue samples 
102 cases which received the institutional or differential diagnosis of histologically defined 
anaplastic pilocytic astrocytoma between 1990 and 2016 were included in the study. The 
original diagnosis was taken for case selection for the series, so some selection bias due to 
changes in diagnostic criteria over the years cannot be excluded. Formalin fixed and paraffin 
embedded tissue of these cases was retrieved from the archives of the following 
Neuropathology departments: Heidelberg, Mannheim, Charité Berlin, Bonn, Duesseldorf, 
Essen, Freiburg, Giessen, Hannover, Cologne, Leipzig, Muenster, Tuebingen,  Wuerzburg, 
Zurich and from the following institutions: the Institute of Pathology, University of Bern; the 
Division of Neuropathology of the Johns Hopkins School of Medicine, Baltimore, Maryland, 
USA; the Mayo Clinic, Rochester, Minnesota, USA; the Division of Neuropathology, UCL 
Institute of Neurology in London; the Department of Cellular Pathology, Queen’s Hospital, 
Romford. In addition, we obtained material via the German Glioma Network. Tissue 
collection and processing as well as data collection were performed in compliance with local 
ethics regulations and approval. 
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Clinical data 
The following clinical data were acquired, when possible: institutional diagnosis, patient 
gender, age at current diagnosis of histologically defined anaplastic pilocytic astrocytoma, 
localization, disease stage (primary surgery or re-resection), history of a precursor lesion, 
history of irradiation, presence of a tumor predisposition syndrome, time to re-surgery and 
overall survival. Time to recurrence was not uniformly available due to different definitions of 
recurrence and different modes of follow-up implemented in the various contributing centers. 
Criteria for outcome analyses are defined below. 
Histological examination 
Hematoxylin and eosin (HE)-stained slides of 74/83 tissue samples of the MC AAP as well as 
all 19 tissue samples of the re-classified tumors were systematically reviewed for 
morphological criteria: general morphological growth pattern, cellularity, nuclear 
pleomorphism, mitoses, necrosis, vascular proliferation, eosinophilic granular bodies or 
Rosenthal fibers and infiltration pattern. The purpose of histological examination was to 
establish, as far as possible, histological features typical for the MC AAP. 
Immunohistochemistry 
For cases with available tissue, immunohistochemistry with antibodies specific for ATRX 
(n=54), H3 K27M (n=47), IDH1 R132H (n=45) or BRAF V600E (n=51) was performed on a 
Ventana BenchMark XT Immunostainer (Ventana Medical Systems, Tucson, Arizona, USA) 
using established protocols. For dilutions and antibody details, see Online Resource 1. 
BRAF V600E, IDH1 R132H and H3 K27M immunohistochemistry was scored as either 
positive or negative. For all three antibodies, nonspecific staining of macrophages, 
eosinophilic granular bodies and calcified deposits was excluded from analysis. Staining of 
vessels or reactive glia was also not considered. Loss of nuclear ATRX expression was 
scored as specific, if over 80% of tumor cell nuclei showed loss of expression, while nuclei of 
non-neoplastic cells, such as endothelia, microglia, lymphocytes and reactive astrocytes, 
were positive. Of note, weak to moderate staining of tumor cell cytoplasm was occasionally 
seen and was considered as non-specific [42]. Slides were scanned on a NanoZoomer 
Digital Slide Scanner (Hamamatsu, Hamamatsu, Japan) and photographed using Aperio 
ImageScope software (v11.0.2.725, Aperio Technologies, Vista, California, USA). 
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DNA extraction and quantification 
DNA was extracted from FFPE tissue using the automated Maxwell system (Promega, 
Fitchburg, Massachusetts, USA) according to the manufacturer’s instructions. DNA 
concentration was determined using the Qubit dsDNA BR Assay kit (Invitrogen, Carlsbad, 
California, USA) following the producer’s guidelines.  
Generation of DNA methylation array data and copy number profile calculation 
From each tissue sample, 200 to 500 ng of DNA were processed for DNA methylation 
analysis. The Infinium HumanMethylation450 Bead-Chip (450k) array (Illumina, Carlsbad, 
California, USA) was used to determine the DNA methylation status of 482,421 CpG sites 
according to the manufacturer’s instructions at the Genomics and Proteomics Core Facility of 
the German Cancer Research Center (DKFZ). A copy number profile (CNP) was calculated 
from the methylation array data as previously described [19] using the ‘conumee’ package in 
R (http://bioconductor.org/packages/release/bioc/html/conumee.html). Amplifications in DNA 
copy number profile were defined as focal regions of copy number gain with a notably higher 
amplitude than regions of suspected single-copy gains. 
H3F3A, BRAF, IDH1, IDH2 and TERT promoter mutation analysis by Sanger 
sequencing 
Primer design and sequencing were performed according to standard protocols. Primer 
sequences and Refseq NM accession numbers for the respective genes are listed in Online 
Resource 2. For the amplification reaction, the following reagents were used:  12.5 µl of Go 
Taq G2 DNA polymerase (Promega), 1.25 µl forward primer (10 pmol/µl), 1.25 µl reverse 
primer (10 pmol/µl), 8.0 µl nuclease free water and 2 µl template DNA (approximately 25 
ng/µl). PCR conditions are listed in Online Resource 3. 
Assessment of MGMT promoter methylation status 
MGMT promoter methylation status was calculated from the methylation data as described 
by Bady et al. [4] with modifications: for each probe, an individual confidence interval for 
MGMT promoter methylation was calculated. If the calculated confidence interval included 
the cutoff value of 0.358 determined by Bady et al., MGMT promoter methylation status was 
defined as not determinable. For cases with an MGMT promoter methylation status not 
determinable by 450k methylation analysis additional pyrosequencing was performed using 
the therascreen® MGMT Pyro® kit (QIAGEN®) and the PyroMark® Q24 system (QIAGEN®) 
according to the manufacturer’s protocol. Bisulfite conversion was done with the EpiTect fast 
DNA bisulfite kit (QIAGEN®). According to studies published by Quillien et al., Felsberg et al. 
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and Reifenberger et al. [11, 38, 40], the cutoff value for MGMT promoter methylation status 
was set as follows: a mean MGMT promoter methylation percentage < 8% across the 
investigated CpG sites was considered as non-methylated and a value ≥ 8% was considered 
as methylated. 
Gene panel sequencing 
Gene panel sequencing was performed and resulting data were analyzed as previously 
described [47]. In brief, extracted DNA was sheared on a M220 Focused-ultrasonicator™ 
(Covaris®, Woburn, Massachusetts, USA). DNA integrity and fragment size were determined 
by the Bioanalyzer 2100 (Agilent, Santa Clara, California, USA). Sequencing was performed 
on a NextSeq 500 instrument (Illumina, Carlsbad, USA) with a mean coverage of 645 reads 
(with a standard deviation of of 455 reads). Gene panel sequencing data were automatically 
annotated using annovar software that integrates information from databases such as 
dbSNP, the 1000 Genomes Project and COSMIC, as well as with SIFT and PolyPhen2 
scores to infer the possible biological relevance of an alteration [55]. Gene panel sequencing 
data were then filtered applying the following criteria: firstly, exonic and splicing variants were 
selected. Among these, synonymous and stoploss variants were not further considered. 
Thereafter, variants with a frequency not exceeding 1% in the healthy population as well as 
undescribed variants were selected according to the 1000 Genomes Project database. 
Variants described as known polymorphisms in the Single Nucleotide Polymorphism 
database (dbSNP, version 138:  
https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?view+summary=view+summar
y&build_id=138) were not considered. Insertions and deletions were filtered for exonic 
frameshift changes that were not yet detected in the healthy population according to the 
1000 Genomes Project database and that were not present in the Single Nucleotide 
Polymorphism database (dbSNP). The remaining items (nonsynonymous, stopgain or splice-
site variants, frameshift insertions and frameshift deletions) were evaluated for their potential 
clinic-pathological relevance using the COSMIC database 
(http://cancer.sanger.ac.uk/cosmic) and the ClinVar database 
(http://www.ncbi.nlm.nih.gov/clinvar/). According to these databases, variants were 
categorized with regard to the probable consequences on protein function as follows: 
damaging, possibly damaging, likely not relevant or no applicable information. Variants 
assessed as damaging or possibly damaging were considered as mutations. Variants 
assessed as likely not relevant or with lack of information about clinical relevance were not 
considered. For the assessment of mutations in genes of the MAPK pathway, we considered 
NF1, BRAF, FGFR1, KRAS, NRAS, HRAS, NTRK2 and PTPN11. A full list of the genes 
represented in the applied gene panel is provided in Online Resource 4. The deFuse 
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software tool (https://sourceforge.net/projects/defuse/, [32]) was used to identify 
KIAA1549:BRAF, FAM131B:BRAF, FGFR1:TACC1 and FGFR3:TACC3 fusions and to 
screen for NTRK2 fusions (QKI:NTRK2, NACC2:NTRK2). Other gene fusions - among these 
other BRAF fusions with rare fusion partners (RNF130:BRAF, CLCN6:BRAF, MKRN1:BRAF, 
GNAI1:BRAF) - were not sufficiently covered by this approach and, hence, were not 
identifiable by the applied methods. 
Reference datasets 
Reference datasets for t-SNE, clustering and copy number analyses: for t-SNE and 
hierarchical clustering, the following glioma reference classes were included: diffuse midline 
glioma, H3 K27 mutant (DMG K27; 14 cases); high-grade neuroepithelial tumor, H3 G34 
mutant (GBM G34; 11 cases); GBM of the midline (GBM MID; 10 cases); GBM, 
mesenchymal subtype (GBM MES; 15 cases); GBM, RTK I subtype (GBM RTK I; 15 cases); 
GBM, RTK II subtype (GBM RTK II; 8 cases); pleomorphic xanthoastrocytoma (PXA; 17 
cases); PA of the supratentorial hemispheres (PA SUP; 12 cases); PA of the posterior fossa 
(PA PF; 15 cases); PA of the midline (PA MID; 18 cases); dysembryoplastic neuroepithelial 
tumor (DNET; 13 cases) and diffuse leptomeningeal glioneuronal tumor (DLGNT; 10 cases). 
Detailed descriptions of the reference methylation classes used in this study are outlined 
under https://www.molecularneuropathology.org [6], (Capper, Jones, Sill, Hovestadt et al., 
Nature 2018, in press). 
Reference sets for the Kaplan Meier analysis: Outcome data were available for 41/83 of the 
MC AAP patients. For patients with an initial diagnosis of a lower-grade glioma, the date of 
the first diagnosis of histologically defined anaplastic pilocytic astrocytoma was considered 
as starting point for the outcome analysis. Kaplan Meier analysis was performed in 
comparison to survival data from additional 281 glioma patients of 5 reference classes: 82 
PAs WHO grade I, 18 PXAs, 26 anaplastic astrocytomas, IDH mutant (AIII IDH mut), 90 
GBMs, IDH mutant (GBM IDH mut) and 56 GBMs, IDH wildtype (GBM IDH wt).  
Statistical analyses 
The DNA methylation array data were processed with the R/Bioconductor package minfi 
(version 1.20) [2]. For unsupervised hierarchical clustering of histologically defined anaplastic 
pilocytic astrocytomas and reference samples, we selected the 20,000 most variably 
methylated CpG sites across the dataset according to median absolute deviation. Pairwise 
similarity of samples was calculated using Euclidean distance. Clusters were then linked 
according to the Ward’s linkage method. The t-SNE plot was computed via the R package 
Rtsne [28] using the 20,000 most variable CpG sites according to standard deviation, 2,000 
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iterations and a perplexity value of 20. To define the MC AAP, cutoffs for the X and the Y 
values were deduced from the t-SNE plot (Fig 1) as follows: -10 < Y < 10 and -20 < X < 2. 
Survival data of MC AAP and reference group patients were evaluated via Kaplan-Meier 
analysis using the JMP software (SAS Institute, Cary, North Carolina, USA). Outcome 
analyses were calculated from the time point of the first histological diagnosis of anaplastic 
pilocytic astrocytoma. Observation time for the Kaplan-Meier analysis was cut at ten years 
(120 months) for all subgroup analyses due to very small numbers of patients remaining 
under observation beyond this. To verify differences of the survival distributions between the 
respective patient groups, the Log-rank test was applied.  
Results 
A subset of histologically defined anaplastic pilocytic astrocytomas share a common 
DNA methylation profile  
We performed DNA methylation analysis of 102 gliomas with the institutional or differential 
diagnosis of anaplastic pilocytic astrocytoma. Unsupervised t-SNE analysis of their DNA 
methylation profiles against 158 reference cases from 12 different glioma DNA methylation 
classes revealed a DNA methylation cluster comprising 83 of these 102 tumors (81%; Fig 1). 
Subgroups within the main group of 83 tumors did not become apparent in the t-SNE 
analysis. The 19 remaining tumors grouped to (or close to) one of the reference classes. Two 
of these showed high similarity to high-grade glioma reference classes (one to DMG K27 and 
the other to GBM MID), two to the PXA reference class and 15 cases were similar to the low-
grade glioma reference classes comprising PAs and DNETs. The 83 tumors in the cohort of 
histologically defined anaplastic pilocytic astrocytomas, henceforth denominated DNA 
methylation class anaplastic astrocytoma with piloid features (MC AAP), were further 
characterized by integration of clinical and molecular features. Of note, the MC AAP also 
contained two tumors with a H3 K27M mutation. Indeed, these lesions were located near the 
midline (one in the third and lateral ventricle and the other in the cerebellum), but did not 
otherwise show histological features of DMG K27, as both cases had a piloid morphology. 
Notably, the MC AAP showed similarity with the methylation profiles of the DLGNT reference 
class. Furthermore, two PA MID reference cases clustered to the MC AAP. 
In addition, we performed an unsupervised clustering analysis of the same cohort as 
analyzed by t-SNE (Online Resource 5). This analysis revealed a cluster in which 81 tumors 
were congruent with the 83 MC AAP tumors identified by t-SNE, confirming the assignment 
as a separate DNA methylation cluster. Within this methylation cluster, two subclusters A and 
B (Online Resource 5) were putatively identified. There was, however, no high consistency in 
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repeated clustering analyses and no obvious clinical, histological or molecular differences to 
further suggest treating these as two independent subclusters. 
Re-classification of tumors with histologically defined anaplastic pilocytic 
astrocytomas, but divergent DNA methylation profile  
t-SNE and clustering analysis revealed that 19 of the 102 tumors with histological features of 
anaplastic pilocytic astrocytoma displayed a DNA methylation profile that differed from the 
MC AAP (Fig 1 and Online Resource 5). In keeping with our experience with other series 
[52], (Capper, Jones, Sill, Hovestadt et al., Nature 2018, in press), the majority of these 
tumors could be re-classified on the basis of re-evaluation of histology and orthogonal 
molecular findings (immunohistochemistry for BRAF V600E, H3 K27M, copy number profile 
analysis): six tumors were downgraded to PA WHO grade I, one case was re-classified as 
PXA, one as diffuse midline glioma with H3 K27M mutation, one as GBM, IDH wildtype and 
two as low grade gliomas, not elsewhere classified (NEC). The remaining eight cases could 
not be definitely classified. Online Resources 6, 7 and 8 give details and show examples of 
re-classified and non-classifiable cases. 
Clinical characteristics of the MC AAP 
The tumors in the MC AAP (n=83) were preferentially located in the posterior fossa (74%), 
most frequently in the cerebellum (63%). 17% were located supratentorially, two cases (2%) 
had a supra- and infratentorial localization and 5 cases (7%) were located in the spinal 
compartment (Fig 2a). Median patient age at resection was 41.5 years with only 8 out of 76 
tumors (11%) occurring in patients below the age of 20 years (Fig 2b). The distribution of 
male and female patients was balanced (male:female ratio of 1.1; n=83). Of 67 patients with 
available data, 42 patients (63%) presented with primary surgery and without previously 
known lesions, whereas the investigated tumors of 25 patients (37%) originated from a re-
resection (Fig 2c). For 8 of these cases (12%) a low-grade primary tumor was known, 3 
cases (4%) were initially diagnosed with histologically defined anaplastic pilocytic 
astrocytoma and 14 cases (17%) had primary tumors with unknown initial grade. Of the 8 
patients with a reported low-grade precursor tumor, 6 had been historically diagnosed as PA, 
one as oligodendroglioma and one as diffuse astrocytoma. Unfortunately, material of these 
cases was not available for histological or molecular re-evaluation. For the 25 re-resected 
lesions, second surgery was performed within 10 years in 18 cases (72%), whereas time to 
re-surgery was longer than 10 years in four cases (16%) and was unknown for another three 
cases (12%). Median overall survival after the first diagnosis of histologically defined 
anaplastic pilocytic astrocytoma was 23.6 months (n=41/83) with a range from 19 days up to 
10.9 years. Median time to re-surgery was 1.2 years with a range from 66 days up to 28.3 
years. For patients with a low-grade primary tumor, median time to re-surgery was 3.2 years 
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(n=6/8), whereas in patients with a high-grade primary tumor, median time to re-surgery was 
only 0.9 years (n=3/3). For only 5% (4 cases) of the patients in the whole cohort, previous 
brain irradiation was documented. A diagnosis of neurofibromatosis type 1 was clinically 
known in one patient and clinically suspected in a second patient. We further cannot exclude 
that some of the other NF1 mutations identified in the tumor series (see below) may have 
also been present in the germline. Other hereditary tumor predisposition syndromes were not 
documented.  
Histological and immunohistochemical characteristics of MC AAP tumors 
We were able to comprehensively evaluate 74/83 cases of the MC AAP histologically 
including the assessment of growth and infiltration pattern, cellularity, nuclear pleomorphism, 
mitotic count, presence of necrosis, vascular proliferation and presence of eosinophilic 
granular bodies and/or Rosenthal fibers. The remaining 9 tumors were not comprehensively 
evaluable because of limited paraffin material. Results are summarized in Fig 3. Examples 
for histological features of the MC AAP are shown in Fig 4a, 4b and 4c. In our series features 
of cortical dysplasia adjacent to the tumors were not obvious in any of the cases. 
Immunohistochemical analysis included assessment of the glioma markers ATRX, BRAF 
V600E, H3 K27M and IDH1 R132H. In 44% (24/54) of MC AAP lesions nuclear ATRX 
expression was lost in the tumor cells (Fig 4d). BRAF immunohistochemistry revealed only 
one positive case (1/51, 2%). By H3 K27M immunohistochemistry and confirmatory Sanger 
sequencing analysis, one case (1/47, 2%) with a H3 K27M mutation was identified (Online 
Resource 9). For all the remaining cases tested by immunohistochemistry, H3 K27M (Fig 4e) 
and BRAF V600E were negative. IDH1 R132H immunohistochemistry was negative in all 
cases investigated (45/45) (Fig 4f).  
DNA copy number aberrations in the MC AAP - CDKN2A/B deletion represents the 
most frequent structural aberration 
Copy number profile analysis of the MC AAP tumors disclosed numerous, partially complex 
chromosomal alterations: in 73 of 83 cases (88%), more than three structural aberrations 
were found, whereas a small subset of 10 cases (12%) exhibited three or fewer alterations. 
Fig 5a illustrates a representative copy number profile of a PA in the posterior fossa, 
whereas in Fig 5b, an example of a copy number profile for a tumor of the MC AAP is shown. 
Fig 5c and d show a summary plot of chromosomal aberrations of 45 PA reference cases 
(comprising 15 cases of posterior fossa PA, 18 cases of midline PA and 12 cases of 
supratentorial PA) and from all 83 tumors of the MC AAP. The most frequent aberration in 
the MC AAP (66/83 cases, 80%) was a deletion of CDKN2A/B, which was frequently 
associated with broader deletions or complex changes on chromosome arm 9p (41/83 cases, 
49%). A further significant finding was a BRAF fusion indicated by a focal low level peak  
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indicative of a tandem duplication on chromosome 7q in 15 out of 74 assessed cases (20%) 
(Fig 5b, 5d, 6). Other recurrent copy number aberrations were gains and/or complex changes 
on chromosome arms 12q (27%) and 17q (33%) as well as deletions on chromosomes 1p 
(19%), 8p (23%) and 19q (22%). A CDK4 amplification was detected in seven cases (8%) 
and this was associated with a concomitant MDM2 amplification in four cases (5%). Other 
recurrent amplifications more commonly seen in GBM (e.g. of MDM4, PDGFRα, EGFR, 
CDK6, MET) were not observed. 
MC AAP tumors harbor mutations in MAPK pathway genes 
Alterations affecting genes encoding members of the mitogen-activated protein kinase 
(MAPK) pathway have previously been found to occur in up to 100% of WHO grade I PAs 
[21-23]. By combining immunohistochemistry, panel sequencing and copy number analysis, 
we were able to comprehensively examine the status of MAPK pathway gene alterations for 
65 of 83 tumors of the MC AAP (Fig 6). In 49 out of these 65 cases (75%), at least one 
characteristic MAPK pathway gene alteration was detected. In notable contrast to typical 
PAs, the most frequently affected gene was NF1, being altered in 20 of 67 lesions (30%). In 
total, five tumors exhibited a deletion, 10 cases harbored a mutation (including one clinically 
known NF1 syndrome patient) and three cases showed both, a deletion in the copy number 
profile and a mutation of the NF1 gene. The remaining two tumors showed 
immunohistochemical loss of NF1 protein expression and a balanced NF1 gene dosage in 
the copy number profile. Since matching constitutional DNA was unfortunately lacking for 
most cases, we cannot comment on the rate of germline versus somatic NF1 alterations in 
the series. BRAF was the second most frequently altered MAPK pathway gene: 15 of 74 
cases (20%) harbored a BRAF fusion and one case (1%) a BRAF V600E mutation. In 12 out 
of 64 cases (19%) an FGFR1 alteration was detected. Among these, 11 of 64 tumors (17%) 
had a point mutation at one of the known hotspots (K656E/N, N546D/K) and one case (2%) 
exhibited an FGFR1:TACC1 fusion. In another two of 64 cases (3%) a KRAS point mutation 
(Q61H in one and V14A in the other) was detected (Fig 6). MAPK pathway gene alterations 
were mutually exclusive with the exception of one case harboring both an NF1 and an 
FGFR1 alteration (Fig 6). The deFuse software tool was used to identify KIAA1549:BRAF, 
FAM131B:BRAF and FGFR1:TACC1 fusions and to screen for NTRK2 fusions. Other gene 
fusions were not sufficiently covered by our gene panel and were thus not identifiable by our 
approach. RNA sequencing was not performed. 
MC AAP tumors frequently display alterations of ATRX, but rarely of TERT 
Alterations in mechanisms of telomere maintenance are well known drivers of tumor 
progression in a variety of entities. In particular, TERT promoter and ATRX mutations are 
frequently described in diffuse gliomas and have been established as useful markers for their 
15 
 
classification and prognostication [37, 41, 42]. Unexpectedly, we found a high rate of ATRX 
alterations in the MC AAP. 74 cases were evaluable for ATRX alterations either by 
immunohistochemical stainings and/or by panel sequencing analysis. From these 74 tumors, 
33 (45%) displayed either a loss of ATRX expression and/or an ATRX mutation. In 15 of 64 
tumors (23%) mutant ATRX was detected by panel sequencing and 24 of 54 tumors (44%) 
showed an immunohistochemical loss of nuclear ATRX expression. For 21 of the latter 24 
cases panel sequencing data were also available: among these, an ATRX mutation was 
confirmed in 12 cases (57%). In the 18 cases with retained nuclear ATRX expression and 
with available panel sequencing data, no ATRX mutation was detected. In summary, an 
ATRX mutation was confirmed in a subset of tumors with immunohistochemical loss of ATRX 
expression by gene panel sequencing. Hence, the sensitivity of our gene panel sequencing 
approach to predict ATRX protein loss was 57%, the specificity being 100%. In a study on 
IDH mutant gliomas, ATRX gene alterations were also not found in a subset of cases with a 
loss of nuclear ATRX expression, suggesting alternative mechanisms of inactivation [58].  
ATRX alterations and TERT promoter mutations are known to occur in a mutually exclusive 
manner in gliomas [25, 42]. To determine the rate of TERT promoter mutations in the MC 
AAP and to explore, whether these are mutually exclusive with ATRX alterations in this newly 
defined tumor class, we performed Sanger sequencing of the TERT promoter region for 74 
tumors of the MC AAP from which 31 cases carried an ATRX alteration (Fig 6). Two tumors 
(3%) with a TERT promoter mutation, both with the nucleotide exchange C228T, were 
identified. Both tumors did not harbor an ATRX alteration. While gain of chromosome 5p was 
observed in approximately 10% of MC AAP tumors, no focal TERT amplifications were seen 
(Fig 5c). 
MGMT promoter hypermethylation is a frequent finding in MC AAP tumors 
In 38 out of 83 tumors of the MC AAP (46%), the MGMT promoter was hypermethylated. 
Another 38 tumors (46%) showed a non-methylated MGMT promoter and in 7 tumors (8%), 
the MGMT promoter methylation status as assessed by array analysis was not determinable 
and MGMT promoter pyrosequencing could not be performed due to lack of material (Fig 6). 
Comparison of the MC AAP with the molecular subtypes of glioma previously 
described by Ceccarelli et al. 
Ceccarelli et al have recently identified a subset of adult diffuse IDH wildtype gliomas within 
The Cancer Genome Atlas (TCGA) data showing a DNA methylation profile distinct from the 
classic-like and mesenchymal-like GBM defined by Sturm et al. [7, 53]. This subset of tumors 
has been shown to be further subdivided into two DNA methylation subclasses, of which one 
shows similarity to GBM and the other to PA. These DNA methylation subclasses have been 
designated “LGm6-GBM” and “PA-like low-grade gliomas” (LGG) [7]. To explore the 
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relatedness of DNA methylation profiles of our MC AAP (n=83) to the PA-like LGG cohort of 
the TCGA series (n=29 tumors of 26 patients), we performed a t-SNE analysis of the two 
series together with the established reference classes (Fig 7). While 5 of 29 PA-like LGG 
clustered more closely to GBM and 14 of 29 clustered more closely to low-grade glioma 
reference classes, the DNA methylation profiles of 10 of these 29 TCGA tumors (7 patients) 
showed high similarity to the MC AAP. Interestingly, the tumors of these 7 patients were also 
enriched for ATRX, but not for BRAF alterations [7]. Among the 5 TCGA tumors which fell 
into the GBM reference classes, one with a H3 G34 and one with a H3 K27 mutation was 
reported [7]. Indeed, these two cases clustered as expected to the GBM G34 and the DMG 
K27 reference methylation class, respectively.  
Outcome analyses  
As this study is a retrospective analysis, availability of clinical data was limited. Outcome 
data were available for 41 of the 83 patients with an MC AAP tumor: by the date of last 
follow-up, 18 patients (44%) had died and 23 patients (56%) were alive. Median overall 
survival was 720 days (23.6 months). Kaplan Meier analysis of these 41 patients against 
outcome data of five glioma reference classes showed a survival probability inferior to 
patients with conventional PA, PXA and IDH mutant anaplastic astrocytoma and comparable 
outcome to patients with IDH mutant GBM, but superior to patients with IDH wildtype GBM 
(Fig 8a). Of note, univariate outcome analysis of patients of the MC AAP with a characteristic 
MAPK pathway gene alteration identified in this study compared to patients for whom such 
an alteration was not detected showed a significantly better prognosis (p=0.032, Fig 8b). 
Kaplan-Meier analysis for the detected individual MAPK pathway gene alterations alone was 
also performed and showed no significant differences of survival probabilities between 
patients with BRAF, NF1 or FGFR1 altered tumors and patients negative for a characteristic 
MAPK pathway gene alteration (Online Resource 10). No significant outcome differences 
were seen in patients with MGMT methylated versus non-methylated tumors (p=0.922) as 
well as in patients with ATRX altered versus ATRX wildtype tumors (p=0.685) (Fig 8c, d). 
Furthermore, outcome analysis dependent on histological criteria (presence/absence of 
necrosis, mitotic count) was performed (n=38). No significant difference in survival probability 
between tumors with versus without necrosis (p=0.468) or with 0, 1-2 versus more than 2 
mitoses (p=0.383) was evident (Online Resource 11). Among the 38 cases with available 
survival data and comprehensive histological review, only two cases showed palisading 
necrosis. Therefore, separate testing for this feature in outcome analysis was not feasible. 
Kaplan Meier analysis was also performed separately for patients with tumors diagnosed 
with histologically defined anaplastic pilocytic astrocytoma on first resection vs. those that 
were diagnosed with histologically defined anaplastic pilocytic astrocytoma on re-resection 
(Online Resource 12). Survival of these two groups did not differ significantly. Due to 
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retrospective inquiry of clinical data for the patient cohort in this study, treatment information 
such as extent of surgery, application of chemotherapy or preoperative performance status 
were not documented in a systematic or standardized fashion. Therefore, a comprehensive 
data set concerning these factors could not be compiled. 
Discussion 
In this study we report a novel class of glial tumors with a common DNA methylation profile 
including many cases with a morphological overlap with PA with anaplasia as described in 
the WHO classification 2016 [29]. However, detailed histological evaluation shows a wide 
range of morphological features that would occasionally be more in line with other tumor 
entities (especially high-grade glioma/GBM). Thus, as with a growing number of CNS tumors, 
the tumor class defined here by DNA methylation profiling (MC AAP) is not exactly congruent 
with PA with anaplasia as defined in the current WHO classification [29]. 
Initially, t-SNE and cluster analysis of the DNA methylation profiles were performed and 
consistently revealed a DNA methylation cluster denominated MC AAP (anaplastic 
astrocytoma with piloid features). The closest resemblance of the DNA methylation profiles of 
these tumors was evident with the reference DNA methylation class of DLGNT (Fig 1, Online 
Resource 5). Indeed, these tumors may be somehow related to PA with anaplasia, since 
they also frequently harbor BRAF fusions, but additionally show other alterations not typically 
found in classical PA (e.g. 1p loss) [6]. In the t-SNE analysis, two cases with H3 K27M 
mutation also clustered to the MC AAP, indicating that this mutation may also occur in these 
tumors. This adds to the notion that H3 K27M mutations are not 100% specific for DMG K27 
but may also occur in other tumors [59]. Further two PA MID reference tumors clustered 
among the MC AAP. This may indicate a certain degree of closer relation of these tumors to 
the MC AAP, but may also be related to technical limitations of t-SNE analyses to classify 
individual tumors. Analysis of a higher number of cases is required to further explore the 
profiles of such histologically low grade lesions clustering to the MC AAP and to identify 
possible subgroups within the MC AAP. 
Our further investigations focused on the clinical, histological and molecular characterization 
of the MC AAP. As also previously reported for a series of histologically defined anaplastic 
pilocytic astrocytomas [44], we observed a higher median patient age in the MC AAP than in 
conventional PAs [5]. In fact, gliomas belonging to the MC AAP mostly arise in adults. Only 
11% (8/76) of these tumors occurred in patients less than 20 years of age. The most frequent 
tumor localization in our series was the posterior fossa (74%) with 63% of the tumors 
originating in the cerebellum. Compared to a previously reported series of histologically 
defined anaplastic pilocytic astrocytomas [44], the posterior fossa localization seems even 
18 
 
more frequent among gliomas of the MC AAP. Importantly, clinical history of radiotherapy 
was reported in only 5% (4/83) of the patients. Thus, the role of irradiation in progression 
from conventional PA to anaplasia (and indeed, whether such progression occurs at all as 
opposed to de novo occurrence of an anaplastic lesion) may require additional investigation 
[1, 44]. Another issue of interest was the exploration of differences in the molecular profiles 
between tumors which were primarily anaplastic and tumors reported to develop from lower 
grade lesions (secondarily anaplastic). Differences between these two groups were not 
obvious in this study. We are currently compiling a series of classic PAs that later recurred as 
anaplastic tumors to explore if the initial tumor already harbored specific molecular features. 
As shown in Fig 3, we observed a wide spectrum of histological features in our series:  most 
of the tumors in the MC AAP showed a piloid or GBM-like general morphological pattern, 
were moderately cellular, had moderate nuclear pleomorphism, at least 1 mitosis per 10 HPF 
and microvascular proliferation. Around one third of the tumors exhibited areas of necrosis 
and one third showed eosinophilic granular bodies or Rosenthal fibers, respectively. In 
summary, morphological characteristics of the MC AAP were not particularly specific and 
may overlap with other low and high-grade gliomas. Despite evidence of typical histological 
features of anaplasia in a small subset of tumors, our investigations revealed that the 
histology of the majority of cases in our series appears rather inconspicuous. Thus, in an 
analogous fashion to other tumors such as IDH mutant gliomas, molecular analysis may be 
required in order to come to a final, integrated diagnosis. With regard to 
immunohistochemistry, the most interesting finding was a loss of nuclear ATRX expression in 
a subset of MC AAP tumors. Besides, Ebrahimi et al. previously did not detect ATRX 
alterations in conventional PAs, but identified one case of histologically defined anaplastic 
pilocytic astrocytoma and one case of BRAF-fused cerebellar GBM with loss of ATRX 
expression [10]. Notably, an ATRX mutation was verified in only a major subset of MC AAP 
tumors. As in a previous study on IDH mutant gliomas, an ATRX mutation was not found in 
all cases with lost ATRX expression. It therefore appears likely that other mechanisms 
besides exonic mutations, such as small deletions, may also result in a functional (and 
immunohistochemical) loss of ATRX protein [58]. 
MGMT promoter methylation status has been shown to have predictive and prognostic value, 
particularly for patients with GBM [14, 26, 33]. This study revealed that MGMT promoter 
hypermethylation was present in approximately half of MC AAP tumors, whereas in a control 
cohort of conventional PAs (n=45), the MGMT status was either non-methylated in most of 
the cases (35/45, 78%) or not determinable in a small subset (10/45, 22%) of tumors. These 
data indicate that MGMT promoter methylation status may be of some diagnostic relevance 
in terms of distinguishing conventional PA from AAP. However, the present data do not 
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provide any evidence for an association of MGMT promoter methylation status with OS 
amongst the MC AAP. Admittedly, the prognostic value of this outcome analysis is very 
limited, as clinical information about previous chemotherapy and applied pharmaceuticals 
(e.g. temozolomide) were not available for most of the cases. 
Another important finding of this study was that the distribution of MAPK pathway gene 
alterations in MC AAP clearly differed from that known for conventional PA. In particular, 
BRAF fusions are known to be the most abundant molecular alteration in conventional PAs 
with a frequency of up to 75%, depending on tumor localization and patient age. The second 
most common alteration in approximately 7% of PAs involves the NF1 gene followed by 
activating BRAF mutations (5%) and FGFR1 hotspot mutations (5%). Rarely (about 1 up to 
2% each) NTRK2 fusions, PTPN11 mutations and RAF1 fusions were described [21, 24]. In 
contrast, with a frequency of only 20%, BRAF fusions were surprisingly rare in the MC AAP, 
whereas NF1 turned out to be the most frequently affected gene being altered in 30% of the 
tumors. It was not possible to determine germline NF1 status in most cases. Furthermore, a 
substantial fraction (19%) of tumors harbored an FGFR1 alteration. Among these, in one 
tumor, an FGFR1:TACC1 fusion was detected, as previously reported in pediatric low-grade 
as well as in high-grade gliomas. This aberration has also been shown to transform primary 
astrocytes into highly proliferating glial tumors [49, 59]. NTRK2 fusions and PTPN11 
mutations were not observed and a KRAS mutation was detectable in only two cases (3%). 
FGFR1 alterations have been described to be preferentially found in extra-cerebellar and 
especially in midline gliomas [8, 24]. However, in the present series, the majority of FGFR1 
mutant cases were located in the posterior fossa (Fig 6). Hence, these data indicate that 
FGFR1 alterations may not be restricted to supratentorial midline localizations. BRAF 
alterations have been described to be less frequent (36% of cases) in adult compared to 
juvenile PAs [36]. In a study conducted by Hasselblatt et al., comparable results were 
obtained with a fraction of BRAF fusions of 30% in patients aged 31-40 years and of 7% in 
patients older than 40 years [16]. As MC AAP is also characterized by a higher patient age, 
the age distribution of BRAF fusions may explain the comparably low fraction of tumors 
positive for a BRAF fusion in the present series. By analysis of copy number profiles of 
classical PAs and MC AAP tumors we observed that CDKN2A/B deletion in a BRAF fusion 
positive astrocytic glioma is highly suggestive for the diagnosis of AAP and makes the 
diagnosis of WHO grade I PA highly unlikely. 
Aberrant activation of the MAPK pathway in PA, particularly by BRAF or RAS activation and 
NF1 inactivation, is thought to trigger oncogene-induced senescence (OIS) via engagement 
of the cyclin dependent kinase inhibitors p16Ink4a, the gene product of CDKN2A, and/or 
p21Waf1. As these proteins trigger cell cycle arrest, they are thought to be associated with the 
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indolent biological and clinical behavior of conventional PAs [21]. Rodriguez et al. observed a 
loss of p16Ink4a in a subset of PAs with anaplastic features [43]. Another study revealed that 
PA patients with immunohistochemical loss of p16Ink4a expression had a shorter overall 
survival than PA patients with retained p16Ink4a expression [39]. These findings raised the 
question, whether the prognosis of patients with an MC AAP tumor may be associated with 
the presence or absence of p16Ink4a. Due to the low case number of only 4 patients with a 
balanced CDKN2A/B copy number and available survival data, outcome analysis for this 
parameter could not be performed. Approximately half of the tumors comprising the MC AAP 
displayed a MAPK pathway gene alteration in combination with a CDKN2A/B deletion. For 
these tumors, impairment of OIS may be likely. ATRX has recently been suggested to also 
play a role in oncogene induced senescence:  Kovatcheva et al. showed that ATRX binds to 
oncogene induced senescence-associated gene loci, particularly to the HRAS gene locus, 
and represses their activity. Conversely, high expression of HRAS is supposed to prevent 
senescence induction [27]. Based on these data, it could be hypothesized, that acquisition of 
an ATRX alteration may represent another mechanism of impairing oncogene induced 
senescence in MAPK-altered tumors, and that this may contribute to the adverse biological 
and clinical behavior of AAPs. 
Existence of anaplastic features in PA has previously been found to be associated with 
decreased overall survival. In one series, outcomes of patients with histologically defined 
anaplastic pilocytic astrocytomas were indeed less favorable in comparison to conventional 
PA patients. Survival data were stated as comparable to WHO grade II and III diffusely 
infiltrative astrocytomas, but still better than grade WHO IV GBMs [44]. Another study 
suggested that patients with histologically defined anaplastic pilocytic astrocytomas may 
have a better prognosis than other high-grade gliomas in adult patients [12]. However, 
Kaplan Meier analysis of MC AAP patients in the present series revealed a survival 
probability worse than patients with IDH mutant anaplastic astrocytoma, WHO grade III and 
comparable to patients with IDH mutant GBM, WHO grade IV (although better than patients 
with IDH wildtype GBM, WHO grade IV). Median overall survival of approximately 720 days 
(23.6 months) was consistent with the results of other authors [44]. Notably, the 
comparability of the outcome data discussed above may be limited, as cases for previously 
performed analyses were selected by histological criteria, whereas for the present series, 
molecular data were additionally taken into account and may have led to a higher 
discrimination selectivity against other glioma entities. Another notable finding of this study 
was that patients with tumors, in which a characteristic MAPK pathway gene alteration was 
detected by the applied methods, were found to survive significantly longer than patients with 
tumors carrying no characteristic MAPK pathway gene alteration. The status of MAPK 
pathway genes in the present series was assessed by copy number profile analysis, Sanger 
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sequencing and panel sequencing. Admittedly, these methods do not cover all rare BRAF 
(e.g. RNF130:BRAF, CLCN6:BRAF, MKRN1:BRAF, GNAI1:BRAF etc.) or RAF1 fusions or 
other rarer events. In contrast, Jones et al. detected MAPK pathway gene alterations in 
96/96 PAs when applying RNA and whole-genome sequencing [24]. Therefore, it is possible 
that some of the MC AAP tumors without a characteristic MAPK pathway gene alteration 
rather harbor rare alterations that we were not able to detect using our approach. Hence, 
further analyses, such as RNA and whole-genome sequencing, are required to explore 
possible alternative alterations in the tumors of the MC AAP and, when indicated, to 
reappraise, whether the absence of MAPK pathway gene alterations may indeed be 
associated with a worse outcome.  
For diagnostic practice it is important to appreciate that the tumors allotted to the MC AAP 
show overlapping histological and/or molecular features to PA, pilocytic astrocytoma with 
anaplastic features, PXA and – to some extent – to DMG K27 and to GBM. In particular, 
PXAs frequently harbor alterations of BRAF (typically V600E mutation) combined with loss of 
CDKN2A/B [26, 56] and PAs frequently show a range of MAPK gene alterations [16, 20, 21]. 
Hence, distinction between the above-named entities may become challenging [30]. Fig 9 
provides a suggestion of an algorithm for the diagnosis of AAP. As indicated, 
immunohistochemical and single parameter molecular analysis may at least help to exclude 
other glioma classes. Nonetheless, comprehensive molecular investigations (such as DNA 
methylation profiling and/or gene panel sequencing) may be necessary to definitively confirm 
this diagnosis.  
In conclusion, we demonstrate that MC AAP tumors are characterized by a common DNA 
methylation profile and recurrent alterations of NF1, BRAF or FGFR1 together with 
CDKN2A/B and ATRX loss as well as MGMT promoter hypermethylation. AAP most often 
arises as a primary tumor in the posterior fossa of young to middle-aged adults, although it 
may possibly also develop secondarily in the context of a lower grade tumor. Further 
investigations are required, in particular on the clinical behavior of these rare tumors, as our 
retrospective data is rather fragmented. Nonetheless, our attempt to molecularly characterize 
histologically defined anaplastic pilocytic astrocytomas may provide a basis for establishing 
the position of the MC AAP in brain tumor classifications and may – at some stage – enable 
a refinement of stratification of patients for clinical trials. 
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Figure 1 
t-SNE analysis of 102 cases with histological features compatible with the diagnosis of 
anaplastic pilocytic astrocytoma, indicated in black, and 158 reference cases of established 
glioma methylation classes, indicated in different colors. Tumors of the same class are 
depicted in one color. For this analysis the 20,000 most variably methylated CPG islands 
were used. 83 of the histologically defined anaplastic pilocytic astrocytomas (colored in 
black) formed one group intermixed by only few other cases and were designated as DNA 
methylation class anaplastic astrocytoma with piloid features (AAP). 19 histologically defined 
anaplastic pilocytic astrocytomas showed similarities to reference methylation classes and 
therefore grouped within these classes in the t-SNE. Reference methylation classes: GBM 
G34 - glioblastoma, IDH wildtype, H3 G34 mutant; DMG K27 - diffuse midline glioma, H3 
K27M mutant; GBM MID - glioblastoma, IDH wildtype, subclass midline; GBM MES - 
glioblastoma, IDH wildtype, subclass mesenchymal; GBM RTK I - glioblastoma, IDH 
wildtype, subclass RTK I; GBM RTK II - glioblastoma, IDH wildtype, subclass RTK II; PXA - 
(anaplastic) pleomorphic xanthoastrocytoma; DLGNT - diffuse leptomeningeal glioneuronal 
tumor; PA SUP - low grade glioma, subclass hemispheric pilocytic astrocytoma and 
ganglioglioma; PA MID - low grade glioma, subclass midline pilocytic astrocytoma; PA PF - 
low grade glioma, subclass posterior fossa pilocytic astrocytoma; DNET - low grade glioma, 
dysembryoplastic neuroepithelial tumor.  
 
Figure 2 
Clinical characteristics of the DNA methylation class AAP: a) tumor localization throughout 
the central nervous system; b) age distribution; c) distribution of clinical presentation as 
either primary lesion or as lesion with either high grade, low grade or unknown grade 
precursor lesion. 
 
Figure 3 
Histological features of the DNA methylation class AAP: in n=74 cases sufficient material for 
evaluation was available. 
 
Figure 4 
Histology and immunohistochemistry of DNA methylation class AAP (MC AAP): a) HE 
stained section depicting a moderately cell dense, moderately pleomorphic glioma with 
multiple eosinophilic granular bodies (black arrows), a mitotic figure (white arrow in the inset) 
and a Rosenthal fiber (white asterisk in the inset; 400-fold magnification); b) HE of another 
MC AAP tumor with glomeruloid vessel proliferation (asterisks; 400-fold magnification); c) HE 
of another, more piloid MC AAP tumor with patchy necrosis in the lower left of the 
micrograph (400-fold magnification); d) ATRX immunohistochemistry (400-fold 
magnification), the tumor cell nuclei show loss of ATRX expression, whereas nuclear ATRX 
expression in vessels and inflammatory cells is retained; e) H3 K27M immunohistochemistry 
(400-fold magnification), negative H3 K27M staining in all but one case; f) IDH1 R132H 
immunohistochemistry (400-fold magnification), all investigated lesions were negative for 
IDH1 R132H. 
 
Figure 5 
Single case examples and summary copy number profiles (CNPs) of conventional pilocytic 
astrocytoma (PA) and the methylation class anaplastic astrocytoma with piloid features (MC 
AAP): a) example of a CNP of conventional PA, the blue arrow indicates a KIAA1549:BRAF 
fusion, other CNP aberrations are rare; b) example of a CNP of an MC AAP tumor, the blue 
arrows indicate a KIAA1549:BRAF fusion and a CDKN2A/B  deletion, numerous further 
chromosomal gains and losses are apparent; c) summary CNP of conventional PA indicating 
a high fraction of cases with a KIAA1549:BRAF fusion (blue arrow) and whole chromosomal 
gains in rare cases, other chromosomal aberrations including chromosomal losses are rarely 
encountered; d) summary CNP of MC AAP with a smaller proportion of cases harboring 
KIAA1549:BRAF and a high proportion of cases with CDKN2A/B deletion (both indicated by 
blue arrows), numerous further chromosomal gains and losses are observed, particularly 
gains of chromosome 12q and 17q, losses of chromosomes 1p, 8p and 19q as well as gains, 
losses or complex changes on chromosome 9p. 
 
Figure 6 
Summary of molecular alterations and patient characteristics for the methylation class 
anaplastic astrocytoma with piloid features. For molecular alterations, black fields indicate the 
presence and blue fields the absence of the respective alteration. Grey fields indicate that 
the lesion was not tested for the specific alteration or that the respective parameter was not 
determinable. Abbrevations: mut – mutation, del – deletion, fus – fusion, meth – methylated. 
 
Figure 7 
t-SNE of DNA methylation profiles of 102 cases with histological features compatible with the 
diagnosis of anaplastic pilocytic astrocytoma (APA hist; blue) and 158 reference gliomas 
colored identically to Figure 1  together with 29 “PA like low-grade gliomas” (PA-like LGG) 
from The Cancer Genome Atlas [8] (black triangles) using the 20,000 most variably 
methylated CPG islands. Ten of 29 PA-like LGG tumors (7 patients*) showed highest 
similarity to the MC AAP (falling in the same area within the t-SNE) while 14 tumors show 
higher similarities with low-grade glioma reference classes and 5 tumors show methylation 
profile similarities with glioblastoma classes. For group abbreviations see legend of Figure 1.   
* Two patients are represented with primary tumor and recurrence(s): 1/1*/1** – primary 
tumor/first recurrence/second recurrence of patient 1; 2/2* – primary tumor/recurrence of 
patient 2  
 
Figure 8 
Outcome analysis of patients with tumors of the methylation class anaplastic astrocytoma 
with piloid features (MC AAP): a) Kaplan Meier analysis of overall survival of MC AAP in 
comparison to reference glioma classes indicates an intermediate outcome reminiscent of 
IDH mutant glioblastoma: b) MC AAP outcome stratified by detection of a characteristic 
MAPK pathway alteration in this study indicates a worse outcome when no such alteration is 
detected; c) no associations with outcome were observed for MGMT promoter methylation 
status or for d) stratification into cases with altered or retained ATRX. From 41 cases with 
survival data, information about the presence or absence of a MAPK alteration was available 
for 34 patients, information about methylation or non-methylation of the MGMT promoter was 
available for 39 patients and information about ATRX status was available for 38 patients. 
Abbreviations: PA – conventional pilocytic astrocytoma; PXA – pleomorphic 
xanthoastrocytoma; A III IDH – anaplastic astrocytoma, IDH mutant, WHO grade III; GBM 
IDH mut – glioblastoma, IDH mutant, WHO grade IV; GBM IDH wt – glioblastoma, IDH 
wildtype, WHO grade IV; mut – mutation; alt – alteration; charact. – characteristic; meth – 
methylated; unmeth – unmethylated, wt- wildtype; OS – overall survival 
 
Figure 9 
 
Diagnostic considerations for the classification of anaplastic astrocytoma with piloid features 
(AAP): PA – conventional pilocytic astrocytoma; PXA – pleomorphic xanthoastrocytoma; 
GBM – glioblastoma; DMG – diffuse midline glioma; MC AAP – methylation class ananpastic 
astrocytoma with piloid freatures 
 
Online Resource 1 
 
Antibodies used for immunohistochemistry. 
 
 
Online Resource 2 
 
Primers used for targeted sequencing. 
 
 
Online Resource 3 
 
PCR conditions for targeted sequencing. 
 
 
Online Resource 4 
 
List of genes examined by panel sequencing. 
 
Online Resource 5 
Unsupervised clustering of DNA methylation patterns of 102 cases with histological features 
compatible with the diagnosis of anaplastic pilocytic astrocytoma with 158 reference gliomas 
from reference methylation classes (as in Figure 1 and 7) using the 20,000 most variably 
methylated CpG islands. Methylation classes are given as colored bars under “Case 
Category”. Localization and MGMT promoter methylation status are shown as colored bars 
below. Unsupervised clustering demonstrates that the majority of histologically defined 
anaplastic pilocytic astrocytomas (APA hist) fall into one DNA methylation cluster. Notably, 
DLGNTs and single cases of DMG K27 show a high relatedness to this cluster and divide the 
MC AAP into two possible subclusters (A and B). Further molecular analysis did not identify 
differences between these putative subclusters and the subclusters were not stable when 
clustering was repeated with other specifications. As in the t-SNE analysis a fraction of the 
histologically defined anaplastic pilocytic astrocytomas cluster into other molecular classes. 
These cases are highly overlapping with the cases that were re-classified by t-SNE. 
Abbreviations: GBM G34 - glioblastoma, IDH wildtype, H3 G34 mutant; DMG K27 - diffuse 
midline glioma, H3 K27M mutant; GBM MID - glioblastoma, IDH wildtype, subclass midline; 
GBM MES - glioblastoma, IDH wildtype, subclass mesenchymal; GBM RTK I - glioblastoma, 
IDH wildtype, subclass RTK I; GBM RTK II - glioblastoma, IDH wildtype, subclass RTK II; 
PXA - (anaplastic) pleomorphic xanthoastrocytoma; DLGNT - diffuse leptomeningeal 
glioneuronal tumor; PA SUP - low grade glioma, subclass hemispheric pilocytic astrocytoma 
and ganglioglioma; PA MID - low grade glioma, subclass midline pilocytic astrocytoma; PA 
PF - low grade glioma, subclass posterior fossa pilocytic astrocytoma; DNET - low grade 
glioma, dysembryoplastic neuroepithelial tumor. 
 
 
Online Resource 6 
 
Re-classified and non-classifiable cases of the initial series of 102 histologically defined 
anaplastic pilocytic astrocytomas (see also Online Resources 7 and 8). A Legend with 
abbreviations is listed below. (NEC – not elsewhere classified) 
 
 
Online Resource 7 
 
Examples of re-classified and non-classifiable cases (see also Online Resource 6): a) HE 
(400-fold magnification) and copy number profile (CNP) of a lesion (case 4* in Online 
Resource 6) which was re-classified as conventional PA and displays only few chromosomal 
aberrations, except for a KIAA1549:BRAF fusion (blue arrow); b) HE (400-fold magnification) 
and CNP of a lesion (case 9* in Online Resource 6) which was re-classified as glioblastoma 
of the midline and displays numerous chromosomal aberrations, among these a PDGFRα 
amplification (blue arrow), this patient is known to suffer from NF1; c) HE (400-fold 
magnification) and CNP of a tumor (case 18* in Online Resource 6) which was non-
classifiable, as histologic features were reminiscent of a pleomorphic astrocytic glioma, 
methylation profile was allotted to the reference group of dysembryoplastic neuroepithelial 
tumor and the CNP showed numerous whole chromosomal gains. 
 
 
Online Resource 8 
 
Examples of re-classified and non-classifiable cases (see also Online Resource 6): a) HE 
and b) BRAF V600E immunohistochemistry (both 400-fold magnification) of a tumor which 
was re-classified as pleomorphic xanthoastrocytoma due to methylation profile, positivity for 
BRAF V600E and a CDKN2A/B deletion (case 7* in Online Resource 6); c) HE and d) H3 
K27M immunohistochemistry (both 400-fold magnification) of a case which fell into the 
methylation class DMG K27, showed a H3 K27M mutation and was accordingly re-classified 
as DMG K27 (case 8* in Online Resource 6); e) HE and f) ATRX immunohistochemistry 
(both 400-fold magnification) of a lesion which was non-classifiable, as DNA methylation 
profile was allotted to PA SUP, morphology was PXA like and no BRAF alterations, but 
ATRX and CDKN2A/B loss were apparent (case 14* in Online Resource 6).  
 
 
Online Resource 9 
 
a) HE and b) H3 K27M immunohistochemistry (400-fold magnification) of a case out of 
the methylation class anaplastic astrocytoma with piloid features with H3 K27M 
mutation. 
 
 
Online Resource 10 
 
Kaplan-Meier analysis of patients with MC AAP tumors stratified for characteristic MAPK 
pathway gene alterations. From 41 cases with survival data, a sum of 32 patients had either 
exactly one of the indicated MAPK gene alterations or no characteristic MAPK gene 
alteration. Differences between the groups were not statistically significant. alt - alteration, 
fus - fusion, charact. – characteristic; OS – overall survival 
 
 
Online Resource 11 
 
Kaplan-Meier analysis of patients with MC AAP tumors stratified by histological criteria: a) by 
presence or absence of necrosis; b) by mitotic count. Among 41 patients with survival data 
comprehensive histological re-evaluation could be performed in 38 cases. Differences in 
overall survival were not statistically significant. (OS – overall survival) 
 
Online Resource 12 
 
Kaplan-Meier analysis of patients with MC AAP tumors stratified for tumors with histological 
diagnoses as anaplastic pilocytic astrocytoma on first resection vs. those that were 
histologically diagnosed as anaplastic pilocytic astrocytoma on re-resection. Among 41 
patients with survival data information about the kind of resection (1st or other) was available 
in 39 cases. Differences in overall survival were not statistically significant. (OS – overall 
survival) 
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Online Recource 1: Antibodies used for immunohistochemistry 
Antibody Manufacturer Clone Catalogue 
No. 
Pretreatment Antibody 
dilution 
Antibody 
incubation 
ATRX Sigma-Aldrich 
poly-
clonal 
HPA001906 CC1, 90 min 1:200 120 min 
H3.3 K27M Merck Millipore 
poly-
clonal 
ABE419 CC1, 64 min 1:500 32 min 
IDH1 
R132H 
Dianova H09 DIA-H09 CC1, 64 min 1:25 32 min 
BRAF 
V600E 
Roche VE1 790-4855 CC1, 64 min 1:5 32 min 
 
“Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, 
CDKN2A/B and ATRX alterations”, Acta Neuropathologica, Reinhardt et al., correspondence: Prof. Dr. David Capper, Institut für 
Neuropathologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Tel. +49 30 450 536498 / Fax +49 30 450 
536940, E-mail: david.capper@charite.de 
 
Online Resource 2: Primers used for Sanger Sequencing (amplification) 
gene accession number primer sequence 
H3F3A NM_002107.4 forward 5′-CATGGCTCGTACAAAGCAGA-3′ 
  reverse 5′-CAAGAGAGACTTTGTCCCATTTTT-3′ 
BRAF NM_004333 forward 5’- TCATAATGCTTGCTCTGATAGGA-3‘ 
  reverse 5‘-GGCCAAAAATTTAATCAGTGGA-3’ 
IDH1 NM_005896 forward 5′-TGATGAGAAGAGGGTTGAGGA-3′ 
  reverse 5′-GCAAAATCACATTATTGCCAAC-3′ 
IDH2 NM_002168 forward 5′-GCTGCAGTGGGACCACTATT-3′ 
  reverse 5′-CTCCACCCTGGCCTACCT-3’ 
TERT promoter NC_000005.9 forward 5′-TTCGCGGGCACAGACG-3’ 
  reverse 5′-GGCCGCGGAAAGGAAG-3’ 
 
“Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, 
CDKN2A/B and ATRX alterations”, Acta Neuropathologica, Reinhardt et al., correspondence: Prof. Dr. David Capper, Institut für 
Neuropathologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Tel. +49 30 450 536498 / Fax +49 30 450 
536940, E-mail: david.capper@charite.de 
 
Online Resource 3: PCR conditions for Sanger Sequencing 
amplification step temperature (°C) duration (s) cycles 
initial denaturation 95  120 1 
denaturation 94 30 35-36 
annealing 57 (62 for TERT) 30 35-36 
elongation 72 25 35-36 
 
“Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, 
CDKN2A/B and ATRX alterations”, Acta Neuropathologica, Reinhardt et al., correspondence: Prof. Dr. David Capper, Institut für 
Neuropathologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Tel. +49 30 450 536498 / Fax +49 30 450 
536940, E-mail: david.capper@charite.de 
 
Online Resource 4: Panel genes
ABL1 FGFR4 NBN “Anaplastic astrocytoma with piloid features, a novel 
ACVR1 FLT3 NDRG2 molecular class of IDH wildtype glioma with recurrent 
AKT1 FOXO3 NF1 MAPK pathway, CDKN2A/B and ATRX alterations”, 
AKT2 FUBP1 NF2 Acta Neuropathologica, Reinhardt et al., correspondence: 
AKT3 GABRA6 NOTCH1 Prof. Dr. David Capper, Institut für Neuropathologie, 
ALK GNA11 NOTCH2 Charité - Universitätsmedizin Berlin, Charitéplatz 1, 
APC GNAQ NRAS 10117 Berlin, Tel. +49 30-450 536498 / Fax -450 536940,
ARID1A GNAS NTRK2 E-mail: david.capper@charite.de
ARID1B H2AFX PCDH8
ARID2 H3F3A PDGFRA
ATM HDAC2 PIK3C2G
ATR HIST1H3B PIK3CA
ATRX HIST1H3C PIK3R1
BCOR HNF1A PPM1D
BRAF HRAS PRKAR1A
BRCA1 IDH1 PTCH1
BRCA2 IDH2 PTCH2
BRPF1 IDO2 PTEN
BRPF3 JAK2 PTPN11
C11ORF95 JAK3 Rad50
CCND1 KDM6A RAF1
CCND2 KDR RB1
CDH1 KIAA0182 RET
CDK4 KIT SETD2
CDK6 KLF4 SMAD4
CDKN2A KLK1 SMARCA2
CDKN2B KRAS SMARCA4
CDKN2C LDB1 SMARCB1
CHEK2 LZTR1 SMARCD1
CHEK2 MDM2 SMARCD2
CIC MDM4 SMARCE1
CREBBP MET SMO
CSF1R MGMT STAG2
CTNNB1 MLH1 SUFU
D2HGDH MLL2 TBR1
DAXX MPL TCF4
DDX3X MRE11A TERT
DICER1 MSH2 TP53
EGFR MSH6 TRAF7
EZH2 MYB TSC1
FBXW7 MYBL1 TSC2
FGFR1 MYC VHL
FGFR2 MYCN
FGFR3 MYL1
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Online Resource 7: Examples of re-classified and non-classifiable cases
pilocytic astrocytoma
glioblastoma of the midline
non classifiable
“Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B 
and ATRX alterations”, Acta Neuropathologica, Reinhardt et al., correspondence: Prof. Dr. David Capper, Institut für Neuropathologie, 
Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Tel. +49 30 450 536498 / Fax +49 30 450 536940, 
E-mail: david.capper@charite.de
HE ATRX
HE H3.3 K27M
HE BRAF V600E
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Online Resource 8: Examples of re-classified and non-classifiable cases 
“Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent 
MAPK pathway, CDKN2A/B and ATRX alterations”, Acta Neuropathologica, Reinhardt et al., correspondence: 
Prof. Dr. David Capper, Institut für Neuropathologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 
10117 Berlin, Tel. +49 30 450 536498 / Fax +49 30 450 536940, E-mail: david.capper@charite.de
HE
a b
Online Resource 9: MC AAP case with H3 K27M mutation
H3 K27M
“Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma 
with recurrent MAPK pathway, CDKN2A/B and ATRX alterations”, Acta Neuropathologica, 
Reinhardt et al., correspondence: Prof. Dr. David Capper, Institut für Neuropathologie, 
Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Tel. +49 30 450 536498 / 
Fax +49 30 450 536940, E-mail: david.capper@charite.de
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Online Resource 10: Survival analysis of MC AAP cases stratified for MAPK pathway 
gene alterations (n = 32)
Number at risk
BRAF fus
FGFR1 alt
no charact.
MAPK alt
NF1 alt
8 2 1 1 1 1 1
8 4 3 2 2 2 1
10 6 5 2 0 0 0
6 2 0 0 0 0 0
“Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent 
MAPK pathway, CDKN2A/B and ATRX alterations”, Acta Neuropathologica, Reinhardt et al., correspondence: 
Prof. Dr. David Capper, Institut für Neuropathologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 
10117 Berlin, Tel. +49 30 450 536498 / Fax +49 30 450 536940, E-mail: david.capper@charite.de
a b
OS (months)
Online Resource 11: Survival analysis of MC AAP cases stratified for necrosis and mitosis (n = 38)
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“Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX 
alterations”, Acta Neuropathologica, Reinhardt et al., correspondence: Prof. Dr. David Capper, Institut für Neuropathologie, Charité - 
Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Tel. +49 30 450 536498 / Fax +49 30 450 536940, E-mail: david.capper@charite.de
Number at risk
no necrosis
necrosis 
28 15 9 3 2 1 1
10 4 3 3 2 2 1
Number at risk
10 2 1 1
> 2 mitoses
no mitosis
1-2 mitoses 21 8 3 1
7 2 0 0
5 1 1
13 4 2
2 1 0
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Online Resource 12: Survival analysis of MC AAP cases stratified for diagnosis of anaplasia 
at first resection (n = 17) and diagnosis of anaplasia at other than first resection (n = 22)
“Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent 
MAPK pathway, CDKN2A/B and ATRX alterations”, Acta Neuropathologica, Reinhardt et al., correspondence: 
Prof. Dr. David Capper, Institut für Neuropathologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 
10117 Berlin, Tel. +49 30 450 536498 / Fax +49 30 450 536940, E-mail: david.capper@charite.de
p = 0.201 
 
0.0
0.2
0.4
0.6
0.8
1.0
0 20 40 60 80 100 120
other resection
1st resection
Number at risk
1st resection
other resection
17 10 6 3 3 2 2
22 12 7 4 2 2 0
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Abstract: Tumors with histological features of pilocytic astrocytoma (PA), but with increased
mitotic activity and additional high-grade features (particularly microvascular
proliferation and palisading necrosis) have often been designated anaplastic pilocytic
astrocytomas. The status of these tumors as a separate entity has not yet been
conclusively demonstrated and molecular features have only been partially
characterized. We performed DNA methylation profiling of 102 histologically defined
anaplastic pilocytic astrocytomas. T-distributed stochastic neighbor embedding (t-SNE)
and hierarchical clustering analysis of these 102 cases against 158 reference cases
from 12 glioma reference classes revealed that a subset of 83 of these tumors share a
common DNA methylation profile that is distinct from the reference classes. These 83
tumors were thus denominated DNA methylation class anaplastic astrocytoma with
piloid features (MC AAP). The 19 remaining tumors were distributed amongst the
previous reference classes, with additional testing confirming the molecular diagnosis
in most cases. Median age of patients with MC AAP was 41.5 years. The most
frequent localization was the posterior fossa (74%). Deletions of CDKN2A/B (66/83,
80%), MAPK pathway gene alterations (49/65, 75%, most frequently affecting NF1,
followed by BRAF and FGFR1) and mutations of ATRX or loss of ATRX expression
(33/74, 45%) were the most common molecular alterations. All tumors were IDH1/2
wildtype. The MGMT promoter was methylated in 38/83 tumors (45%). Outcome
analysis confirmed an unfavorable clinical course in comparison to PA, but better than
IDH wildtype glioblastoma (GBM). In conclusion, we show that a subset of
histologically defined anaplastic pilocytic astrocytomas forms a separate DNA
methylation cluster, harbors recurrent alterations in MAPK pathway genes in
combination with alterations of CDKN2A/B and ATRX, affects patients who are on
average older than those diagnosed with PA and has an intermediate clinical outcome.
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Re: Resubmission of the manuscript entitled “Anaplastic pilocytic astrocytoma is characterized 
by a distinct DNA methylation profile and high rates of MAPK pathway, CDKN2A/B and ATRX 
alterations”, ANEU-D-17-00955 
 
 
Werner Paulus 
Editor-in-Chief, Acta Neuropathologica 
 
Institute of Neuropathology  
University Hospital Muenster 
Pottkamp 2 
D-48149 Muenster 
Germany  
 
 
Dear Professor Paulus, dear Werner, 
 
we would like to thank the reviewer for the constructive suggestions and we would like to thank 
you for the opportunity to re-revise our manuscript with the updated title “Anaplastic astrocytoma 
with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK 
pathway, CDKN2A/B and ATRX alterations”. We believe that the suggested edits have led to 
substantial improvement. 
 
Please find our point-by-point reply to the editorial and reviewer comments below including how 
and where the manuscript has been modified. All text changes are marked in yellow in the re-
revised manuscript.  
We hope that the manuscript is acceptable for publication in Acta Neuropathologica in the 
current from. 
Thank you for your consideration, 
 
Yours sincerely on behalf of the authors, 
 
 
Annekathrin Reinhardt and David Capper 
 
response to reviewer's comments Click here to download response to reviewer's comments
14.03.18_ResponseLetter_FINAL_Revision2.docx
Point-by-point replies to the reviewer's comments: 
 
Reviewer 2 
The authors have provided a point-by-point reply to the comments. The responses are 
interpreted as follows 
 
1. This reviewer believes that there is still a circular argument to define the term Anaplastic 
Pilocytic Astrocytoma on methylation profiling. While methylation profiling can be a strong tool to 
characterize, the authors' figure 1 demonstrates that the methylation profiles of tumors classified 
as Anaplastic Pilocytic Astrocytoma spans a much larger area compared to other tumors and 
includes a few other tumors such as diffuse midline glioma and diffuse leptomeningeal 
glioneuronal tumor. It is more prudent to have considered methylation profiling in this study as 
the test rather than the gold standard, since considering the methylation profile as the diagnostic 
criterion provides a circular argument about other (genetic and phenotypic) characteristics of 
these tumors. The authors' answer to this section creates even further circular arguments about 
the definition of anaplastic pilocytic astrocytomas, which confirm the possibility that this group 
may represent more than one entity. The manuscript should represent this uncertainty and the 
lack of gold standard: There are data in this manuscript that MAPK altered tumors had a 
different overall survival probability from non-MAPK tumors as reported through KM analysis. 
The additional in comparison to TGCA data also shows that the group identified as MC APA 
may harbor other entities that cluster genetically with other low (or high) grade gliomas. All 
these suggest that the methylation profiling may have classified a number of tumors in the APA 
category, whereas these tumors could have been classified as other entities based on histology 
and genomic alterations. It is still advisable to acknowledge the healthy level of uncertainty for 
individual tumors based on methylation profiling. Finally, I believe if the authors begin with a 
group of cases with a specific methylation pattern, they should also retitle their manuscript to 
suggest that they characterize a series of tumors with a methylation profile 
referred to as "MC APA" that show high rates of MAPK, CDKN2A and ATRX alterations and 
often with an anaplastic pilocytic astrocytoma phenotype/morphology. This may eliminate the 
criticism that some of the tumors they have included in the study may not have been correctly 
classified as APA.  
Reply: We thank the reviewer for that critical point of view that we conveyed in our manuscript 
by the following changes. 
a) We mentioned in the results and in the discussion section that the methylation cluster 
defined in this work may show overlaps with the methylation profiles of tumors of other 
entities and acknowledged technical limitations of t-SNE analysis to classify individual 
tumors. 
 
Changes in the results section: 
“Notably, the MC AAP showed similarity with the methylation profiles of the DLGNT 
reference class. Furthermore, two PA MID reference cases clustered to the MC AAP.” 
 
Changes in the discussion section: 
“The closest resemblance of the DNA methylation profiles of these tumors was evident 
with the reference DNA methylation class of DLGNT … In the t-SNE analysis, two cases 
with H3 K27M mutation also clustered to the MC AAP, indicating that this mutation may 
also occur in these tumors. This adds to the notion that H3 K27M mutations are not 
100% specific for DMG K27 but may also occur in other tumors [59]. Further two PA MID 
reference tumors clustered among the MC AAP. This may indicate a certain degree of 
closer relation of these tumors to the MC AAP, but may also be related to technical 
limitations of t-SNE analyses to classify individual tumors. Analysis of a higher number of 
cases is required to further explore the profiles of such histologically low grade lesions 
clustering to the MC AAP and to identify possible subgroups within the MC AAP.” 
 
b) To avoid confusion with the morphological diagnosis of anaplastic pilocytic 
astrocytoma/pilocytic astrocytoma with anaplastic features and to clearly demarcate the 
methylation cluster we described from these histological terms, we changed the name of 
the methylation cluster from “methylation class anaplastic pilocytic astrocytoma” (“MC 
APA”) to “methylation class anaplastic astrocytoma with piloid features” (“MC AAP”) 
throughout the manuscript. Furthermore, discussions with clinicians also revealed that 
the wording “pilocytic” may be clinically misleading with respect to the adverse prognosis 
of the cases investigated. This also prompted us to change the designation “MC APA” to 
“MC AAP”. 
 
2. The authors acknowledge lack of comprehensive clinical data in the manuscript, which is 
acceptable. 
Reply: We would like to thank the reviewer again for mentioning this point and we thank the 
reviewer for the appreciation. 
 
3. Lack of treatment information should be acknowledged in outcome analysis- it is acceptable 
that the authors have little or no treatment information, but this should be acknowledged on 
page 16 (outcome analysis) since it can impact outcome analysis 
Reply: We thank the reviewer for the indication. Accordingly, we announced the lack of 
treatment information also on page 16. 
 
Changes on page 16: 
“As this study is a retrospective analysis, availability of clinical data was limited. … Due to 
retrospective inquiry of clinical data for the patient cohort in this study, treatment information 
such as extent of surgery, application of chemotherapy or preoperative performance status were 
not documented in a systematic or standardized fashion. Therefore, a comprehensive data set 
concerning these factors could not be compiled.” 
 4. For the selection of cases, a selection bias should be acknowledged. Since the authors 
collected cases from a long period (1990-2016) and diagnostic criteria may have changed 
numerous times over this period, the cases they have identified may be subjected to a selection 
bias. Otherwise, their response is acceptable. 
Reply: We thank the reviewer for the advice and acknowledged the problem of changing 
diagnostic criteria in the materials and methods section. 
 
Changes in the materials and methods section: 
“102 cases which received the institutional or differential diagnosis of histologically defined 
anaplastic pilocytic astrocytoma between 1990 and 2016 were included in the study. The 
original diagnosis was taken for case selection for the series, so a selection bias due to changes 
in diagnostic criteria over the years is possible” 
 
5. Changes made are acceptable. 
 
Reply: Thanks for acknowledging our efforts.   
 
6. Additional data are helpful to understand this, but the provided KM graph is somewhat 
erroneous. It shows that all 39 patients died at month 130. The latter part of the graph is 
probably a plotting error rather than all patients dying in both groups. Also, the lack of statistical 
between two groups is probably due to limited number of occurrences in the 1st resection group 
(red-line) rather than actuarial equality of survival probabilities. There is also a minor problem 
with the KM analysis. The authors state outcome information available for 41 cases but the 
graph includes 39 cases. Why were two cases excluded?  
 
Reply: We appreciate the detailed review of the Kaplan Meier analyses. Indeed, from 41 cases 
with available outcome data, manifestation (first diagnosis or recurrence) was known for only 39 
cases. Hence, the two cases from which manifestation was unknown were excluded. Moreover, 
we added a comment to each legend of a figure showing a Kaplan Meier analysis clarifying how 
many of the 41 cases with outcome data were evaluable for the respective parameters 
investigated. To avoid misunderstandings, we determined an observation time of ten years (120 
months) for the Kaplan Meier analyses and mentioned this in the materials and methods 
section. We also added a table with the number of patients at risk in online resources 11 and 
12. 
 
Changes in the figure legends: 
 
Legend figure 8: 
“From 41 cases with survival data, information about the presence or absence of a MAPK 
alteration was available for 34 patients, information about methylation or non-methylation of the 
MGMT promoter was available for 39 patients and information about ATRX status was available 
for 38 patients.” 
 Legend online resource 10:  
“From 41 cases with survival data, a sum of 32 patients had either exactly one of the indicated 
MAPK gene alterations or no characteristic MAPK gene alteration.” 
 
Legend online resource 11: 
“Among 41 patients with survival data comprehensive histological re-evaluation could be 
performed in 38 cases.” 
 
Legend online resource 12: 
“Among 41 patients with survival data information about the kind of resection (1st or other) was 
available in 39 cases.” 
 
Changes in the materials and methods section: 
“Observation time for the Kaplan-Meier analysis was cut at ten years (120 months) for all 
subgroup analyzes due to very small numbers of patients remaining under observation beyond 
this.” 
 
7. See item 6, I think there is a problem with either the number of cases with adequate follow-up 
or the cases included in the KM analysis. 
 
Reply: We would like to refer to the explanations in our reply to comment 6. 
 
8. The explanations are acceptable 
 
Reply: Thanks for acknowledging our explanations. 
 
9. The explanations are acceptable. However as stated in #1, it may be wiser to retitle the study 
to suggest that particular methylation profile is used as the standard. 
Reply: We are thankful for this important advice. To avoid confusion with the terms anaplastic 
pilocytic astrocytoma and pilocytic astrocytoma with piloid features which are rather used as a 
morphological diagnosis and to clarify that the tumor group we characterized in this manuscript 
resulted from molecular analyzes we retitled our manuscript as follows:  
 
“Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with 
recurrent MAPK pathway, CDKN2A/B and ATRX alterations”. 
 
Additionally, we would like to refer to the explanations in our reply to comment 1. 
 
11. Changes are acceptable. 
 Reply: We thank the reviewer for accepting the changes. 
 
12. Explanations are acceptable. The authors can mention this in their discussion about future 
prospects (not necessary). 
Reply: We would like to thank the reviewer for this important proposal. Accordingly, we added a 
paragraph to the discussion section addressing the issue of molecular differences between 
initially low grade and initially anaplastic AAPs and between pairs of firstly and re-resected 
tumors from the same patient. 
Added paragraph to the discussion section: 
 
“Another issue of interest was the exploration of differences in the molecular profiles between 
tumors which were primarily anaplastic and tumors reported to develop from lower grade lesions 
(secondarily anaplastic). Differences between these two groups were not obvious in this study. 
We are currently compiling a series of classic PAs that later recurred as anaplastic tumors to 
explore if the initial tumor already harbored specific molecular features.” 
 
13. The explanations are acceptable. 
 
Reply: Thanks for acknowledging our explanations. 
 
14. The explanations are acceptable. However, the authors do not clearly acknowledge in the 
manuscript that there may be other entities or groups within the MC APA category, as they 
acknowledge in their response. This reviewer suggests the use of a clear designation of a most 
reasonable gold standard (histological or other), and compare this gold standard with the 
methylation profile to validate the methylation pattern. 
 
Reply: We would like to thank the reviewer for mentioning this issue. To our knowledge, there is 
no further gold standard to unmistakably and comprehensively identify AAP. This tumor group 
was defined by unsupervised clustering analysis and t-SNE of methylation profiles and was 
subsequently described by clinical data, histological features and molecular alterations. Indeed, 
histological overlap with anaplastic pilocytic astrocytomas or – as defined in the WHO 
classification 2016 – pilocytic astrocytomas with anaplastic features, was evident. We 
furthermore acknowledged in the manuscript, that the methylation cluster described here 
contains a subset of uncharacterized tumors and few tumors of other entities (see also our reply 
to comment 1). In summary we would like to recommend taking clinical information, histology, 
methylation profile and molecular alterations into account to come to an integrated diagnosis. 
  
Other changes in the manuscript 
 
We modified and shifted one paragraph from the results to the discussion section: 
 
“Notably, an ATRX mutation was verified in only a major subset of MC AAP tumors. As in a 
previous study on IDH mutant gliomas, an ATRX mutation was not found in all cases with lost 
ATRX expression. It therefore appears likely that other mechanisms besides exonic mutations, 
such as small deletions, may also result in a functional (and immunohistochemical) loss of 
ATRX protein [58].” 
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Abstract 
Tumors with histological features of pilocytic astrocytoma (PA), but with increased mitotic 
activity and additional high-grade features (particularly microvascular proliferation and 
palisading necrosis) have often been designated anaplastic pilocytic astrocytomas. The 
status of these tumors as a separate entity has not yet been conclusively demonstrated and 
molecular features have only been partially characterized. We performed DNA methylation 
profiling of 102 histologically defined anaplastic pilocytic astrocytomas. T-distributed 
stochastic neighbor embedding (t-SNE) and hierarchical clustering analysis of these 102 
cases against 158 reference cases from 12 glioma reference classes revealed that a subset 
of 83 of these tumors share a common DNA methylation profile that is distinct from the 
reference classes. These 83 tumors were thus denominated DNA methylation class 
anaplastic astrocytoma with piloid features (MC AAP). The 19 remaining tumors were 
distributed amongst the previous reference classes, with additional testing confirming the 
molecular diagnosis in most cases. Median age of patients with MC AAP was 41.5 years. 
The most frequent localization was the posterior fossa (74%). Deletions of CDKN2A/B 
(66/83, 80%), MAPK pathway gene alterations (49/65, 75%, most frequently affecting NF1, 
followed by BRAF and FGFR1) and mutations of ATRX or loss of ATRX expression (33/74, 
45%) were the most common molecular alterations. All tumors were IDH1/2 wildtype. The 
MGMT promoter was methylated in 38/83 tumors (45%). Outcome analysis confirmed an 
unfavorable clinical course in comparison to PA, but better than IDH wildtype glioblastoma 
(GBM). In conclusion, we show that a subset of histologically defined anaplastic pilocytic 
astrocytomas forms a separate DNA methylation cluster, harbors recurrent alterations in 
MAPK pathway genes in combination with alterations of CDKN2A/B and ATRX, affects 
patients who are on average older than those diagnosed with PA and has an intermediate 
clinical outcome. 
Key words 
anaplastic pilocytic astrocytoma; pilocytic astrocytoma with anaplasia; methylation profile 
based classification; panel sequencing; ATRX; BRAF; NF1; FGFR1; MGMT; CDKN2A/B; 
molecular characterization; DNA copy number alterations 
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Introduction 
PA accounts for approximately 5% of gliomas across all age groups and for approximately 
25% of all brain tumors encountered in pediatric neurosurgical practice [8, 50], thereby 
representing the most common primary brain tumor in patients of 0 to 19 years of age. In 
contrast, the majority of gliomas in adults are either diffuse gliomas with IDH1 mutation 
(either 1p19q co-deleted or 1p19q intact) or highly malignant GBMs [54]. Where gross total 
resection is feasible, clinical outcome of PA is usually favorable with 10 year overall survival 
rates of around 95% [8, 9, 13, 44]. The vast majority of PAs harbor single genetic alterations 
in genes encoding proteins of the mitogen-activated protein kinase (MAPK) pathway, with the 
most frequent findings being fusions of BRAF with KIAA1549 or rarely other genes, BRAF 
V600E point mutation, or alterations of NF1, FGFR1 or NTRK family genes [24]. Different 
localizations of PA are associated with different frequencies of molecular alterations, with 
posterior fossa tumors harboring a BRAF fusion in up to 80-90% of cases and supratentorial 
lesions showing this alteration in only about 60% of cases [20, 21]. Of further interest is the 
reported age association of BRAF fusions that seem to be less frequent in the adult 
population (e.g. 30% of patients of 31-40 years and 7% of patients older than 40 years of 
age) [16, 21]. To date, BRAF fusions are considered a molecular hallmark of WHO grade I 
PA with a typically favorable outcome [17, 20, 46]. Rare cases of PA, particularly in older 
patients, can have a more aggressive clinical behavior [3, 5, 43, 44, 50, 57]. The tumors of 
these patients may show anaplastic histological features including increased nuclear atypia, 
increased mitotic activity, prominent endothelial proliferation and/or palisading necrosis and 
have been discussed to represent a separate entity or subentity [44]. In the WHO 
classification 2016, this glioma subgroup is designated pilocytic astrocytoma with anaplasia. 
The identification of this particular subset of more aggressively behaving tumors is 
challenging, as the histological features described in the WHO classification do not exclude 
the diagnosis of conventional PA WHO grade I [8, 44], while histological overlap with 
pleomorphic xanthoastrocytoma/anaplastic pleomorphic xanthoastrocytoma and GBM is also 
evident. Moreover, according to the WHO classification, grading and nomenclature of 
pilocytic astrocytoma with anaplasia are still to be conclusively defined [29]. One study on the 
molecular characterization of clinically aggressive/recurrent or histologically defined 
anaplastic pilocytic astrocytomas revealed a heterozygous PTEN/10q loss in 6 of 19 (32%) 
and a homozygous CDKN2A/B deletion in 3 of 15 (20%) cases with BRAF fusions identified 
in 63% of cerebellar lesions [43]. A different study observed an association with 
neurofibromatosis type I in 28% of histologically defined anaplastic pilocytic astrocytomas 
[15]. Nevertheless, more comprehensive approaches are necessary to establish the 
characteristic molecular profile of this tumor class. 
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Recently, DNA methylation profiling has become an important adjunct tool for tumor 
classification and identification of molecular subclasses [18, 31, 34, 35, 45, 48, 51, 52]. To 
molecularly characterize histologically defined anaplastic pilocytic astrocytomas, we 
analyzed a retrospective series of 102 cases with histological features of this putative entity 
by DNA methylation profiling, DNA copy number analysis, next generation gene panel 
sequencing as well as by histological characterization and correlated these data with clinical 
information. Herein, we report that a major subset (83/102, 81%) of these tumors show a 
common DNA methylation profile, harbor frequent MAPK pathway gene alterations and have 
additional molecular and clinical features that clearly distinguish them from WHO grade I PAs 
as well as from other adult diffuse gliomas. 
Materials and Methods 
Tissue samples 
102 cases which received the institutional or differential diagnosis of histologically defined 
anaplastic pilocytic astrocytoma between 1990 and 2016 were included in the study. The 
original diagnosis was taken for case selection for the series, so some selection bias due to 
changes in diagnostic criteria over the years cannot be excluded. Formalin fixed and paraffin 
embedded tissue of these cases was retrieved from the archives of the following 
Neuropathology departments: Heidelberg, Mannheim, Charité Berlin, Bonn, Duesseldorf, 
Essen, Freiburg, Giessen, Hannover, Cologne, Leipzig, Muenster, Tuebingen,  Wuerzburg, 
Zurich and from the following institutions: the Institute of Pathology, University of Bern; the 
Division of Neuropathology of the Johns Hopkins School of Medicine, Baltimore, Maryland, 
USA; the Mayo Clinic, Rochester, Minnesota, USA; the Division of Neuropathology, UCL 
Institute of Neurology in London; the Department of Cellular Pathology, Queen’s Hospital, 
Romford. In addition, we obtained material via the German Glioma Network. Tissue 
collection and processing as well as data collection were performed in compliance with local 
ethics regulations and approval. 
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Clinical data 
The following clinical data were acquired, when possible: institutional diagnosis, patient 
gender, age at current diagnosis of histologically defined anaplastic pilocytic astrocytoma, 
localization, disease stage (primary surgery or re-resection), history of a precursor lesion, 
history of irradiation, presence of a tumor predisposition syndrome, time to re-surgery and 
overall survival. Time to recurrence was not uniformly available due to different definitions of 
recurrence and different modes of follow-up implemented in the various contributing centers. 
Criteria for outcome analyses are defined below. 
Histological examination 
Hematoxylin and eosin (HE)-stained slides of 74/83 tissue samples of the MC AAP as well as 
all 19 tissue samples of the re-classified tumors were systematically reviewed for 
morphological criteria: general morphological growth pattern, cellularity, nuclear 
pleomorphism, mitoses, necrosis, vascular proliferation, eosinophilic granular bodies or 
Rosenthal fibers and infiltration pattern. The purpose of histological examination was to 
establish, as far as possible, histological features typical for the MC AAP. 
Immunohistochemistry 
For cases with available tissue, immunohistochemistry with antibodies specific for ATRX 
(n=54), H3 K27M (n=47), IDH1 R132H (n=45) or BRAF V600E (n=51) was performed on a 
Ventana BenchMark XT Immunostainer (Ventana Medical Systems, Tucson, Arizona, USA) 
using established protocols. For dilutions and antibody details, see Online Resource 1. 
BRAF V600E, IDH1 R132H and H3 K27M immunohistochemistry was scored as either 
positive or negative. For all three antibodies, nonspecific staining of macrophages, 
eosinophilic granular bodies and calcified deposits was excluded from analysis. Staining of 
vessels or reactive glia was also not considered. Loss of nuclear ATRX expression was 
scored as specific, if over 80% of tumor cell nuclei showed loss of expression, while nuclei of 
non-neoplastic cells, such as endothelia, microglia, lymphocytes and reactive astrocytes, 
were positive. Of note, weak to moderate staining of tumor cell cytoplasm was occasionally 
seen and was considered as non-specific [42]. Slides were scanned on a NanoZoomer 
Digital Slide Scanner (Hamamatsu, Hamamatsu, Japan) and photographed using Aperio 
ImageScope software (v11.0.2.725, Aperio Technologies, Vista, California, USA). 
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DNA extraction and quantification 
DNA was extracted from FFPE tissue using the automated Maxwell system (Promega, 
Fitchburg, Massachusetts, USA) according to the manufacturer’s instructions. DNA 
concentration was determined using the Qubit dsDNA BR Assay kit (Invitrogen, Carlsbad, 
California, USA) following the producer’s guidelines.  
Generation of DNA methylation array data and copy number profile calculation 
From each tissue sample, 200 to 500 ng of DNA were processed for DNA methylation 
analysis. The Infinium HumanMethylation450 Bead-Chip (450k) array (Illumina, Carlsbad, 
California, USA) was used to determine the DNA methylation status of 482,421 CpG sites 
according to the manufacturer’s instructions at the Genomics and Proteomics Core Facility of 
the German Cancer Research Center (DKFZ). A copy number profile (CNP) was calculated 
from the methylation array data as previously described [19] using the ‘conumee’ package in 
R (http://bioconductor.org/packages/release/bioc/html/conumee.html). Amplifications in DNA 
copy number profile were defined as focal regions of copy number gain with a notably higher 
amplitude than regions of suspected single-copy gains. 
H3F3A, BRAF, IDH1, IDH2 and TERT promoter mutation analysis by Sanger 
sequencing 
Primer design and sequencing were performed according to standard protocols. Primer 
sequences and Refseq NM accession numbers for the respective genes are listed in Online 
Resource 2. For the amplification reaction, the following reagents were used:  12.5 µl of Go 
Taq G2 DNA polymerase (Promega), 1.25 µl forward primer (10 pmol/µl), 1.25 µl reverse 
primer (10 pmol/µl), 8.0 µl nuclease free water and 2 µl template DNA (approximately 25 
ng/µl). PCR conditions are listed in Online Resource 3. 
Assessment of MGMT promoter methylation status 
MGMT promoter methylation status was calculated from the methylation data as described 
by Bady et al. [4] with modifications: for each probe, an individual confidence interval for 
MGMT promoter methylation was calculated. If the calculated confidence interval included 
the cutoff value of 0.358 determined by Bady et al., MGMT promoter methylation status was 
defined as not determinable. For cases with an MGMT promoter methylation status not 
determinable by 450k methylation analysis additional pyrosequencing was performed using 
the therascreen® MGMT Pyro® kit (QIAGEN®) and the PyroMark® Q24 system (QIAGEN®) 
according to the manufacturer’s protocol. Bisulfite conversion was done with the EpiTect fast 
DNA bisulfite kit (QIAGEN®). According to studies published by Quillien et al., Felsberg et al. 
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and Reifenberger et al. [11, 38, 40], the cutoff value for MGMT promoter methylation status 
was set as follows: a mean MGMT promoter methylation percentage < 8% across the 
investigated CpG sites was considered as non-methylated and a value ≥ 8% was considered 
as methylated. 
Gene panel sequencing 
Gene panel sequencing was performed and resulting data were analyzed as previously 
described [47]. In brief, extracted DNA was sheared on a M220 Focused-ultrasonicator™ 
(Covaris®, Woburn, Massachusetts, USA). DNA integrity and fragment size were determined 
by the Bioanalyzer 2100 (Agilent, Santa Clara, California, USA). Sequencing was performed 
on a NextSeq 500 instrument (Illumina, Carlsbad, USA) with a mean coverage of 645 reads 
(with a standard deviation of of 455 reads). Gene panel sequencing data were automatically 
annotated using annovar software that integrates information from databases such as 
dbSNP, the 1000 Genomes Project and COSMIC, as well as with SIFT and PolyPhen2 
scores to infer the possible biological relevance of an alteration [55]. Gene panel sequencing 
data were then filtered applying the following criteria: firstly, exonic and splicing variants were 
selected. Among these, synonymous and stoploss variants were not further considered. 
Thereafter, variants with a frequency not exceeding 1% in the healthy population as well as 
undescribed variants were selected according to the 1000 Genomes Project database. 
Variants described as known polymorphisms in the Single Nucleotide Polymorphism 
database (dbSNP, version 138:  
https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?view+summary=view+summar
y&build_id=138) were not considered. Insertions and deletions were filtered for exonic 
frameshift changes that were not yet detected in the healthy population according to the 
1000 Genomes Project database and that were not present in the Single Nucleotide 
Polymorphism database (dbSNP). The remaining items (nonsynonymous, stopgain or splice-
site variants, frameshift insertions and frameshift deletions) were evaluated for their potential 
clinic-pathological relevance using the COSMIC database 
(http://cancer.sanger.ac.uk/cosmic) and the ClinVar database 
(http://www.ncbi.nlm.nih.gov/clinvar/). According to these databases, variants were 
categorized with regard to the probable consequences on protein function as follows: 
damaging, possibly damaging, likely not relevant or no applicable information. Variants 
assessed as damaging or possibly damaging were considered as mutations. Variants 
assessed as likely not relevant or with lack of information about clinical relevance were not 
considered. For the assessment of mutations in genes of the MAPK pathway, we considered 
NF1, BRAF, FGFR1, KRAS, NRAS, HRAS, NTRK2 and PTPN11. A full list of the genes 
represented in the applied gene panel is provided in Online Resource 4. The deFuse 
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software tool (https://sourceforge.net/projects/defuse/, [32]) was used to identify 
KIAA1549:BRAF, FAM131B:BRAF, FGFR1:TACC1 and FGFR3:TACC3 fusions and to 
screen for NTRK2 fusions (QKI:NTRK2, NACC2:NTRK2). Other gene fusions - among these 
other BRAF fusions with rare fusion partners (RNF130:BRAF, CLCN6:BRAF, MKRN1:BRAF, 
GNAI1:BRAF) - were not sufficiently covered by this approach and, hence, were not 
identifiable by the applied methods. 
Reference datasets 
Reference datasets for t-SNE, clustering and copy number analyses: for t-SNE and 
hierarchical clustering, the following glioma reference classes were included: diffuse midline 
glioma, H3 K27 mutant (DMG K27; 14 cases); high-grade neuroepithelial tumor, H3 G34 
mutant (GBM G34; 11 cases); GBM of the midline (GBM MID; 10 cases); GBM, 
mesenchymal subtype (GBM MES; 15 cases); GBM, RTK I subtype (GBM RTK I; 15 cases); 
GBM, RTK II subtype (GBM RTK II; 8 cases); pleomorphic xanthoastrocytoma (PXA; 17 
cases); PA of the supratentorial hemispheres (PA SUP; 12 cases); PA of the posterior fossa 
(PA PF; 15 cases); PA of the midline (PA MID; 18 cases); dysembryoplastic neuroepithelial 
tumor (DNET; 13 cases) and diffuse leptomeningeal glioneuronal tumor (DLGNT; 10 cases). 
Detailed descriptions of the reference methylation classes used in this study are outlined 
under https://www.molecularneuropathology.org [6], (Capper, Jones, Sill, Hovestadt et al., 
Nature 2018, in press). 
Reference sets for the Kaplan Meier analysis: Outcome data were available for 41/83 of the 
MC AAP patients. For patients with an initial diagnosis of a lower-grade glioma, the date of 
the first diagnosis of histologically defined anaplastic pilocytic astrocytoma was considered 
as starting point for the outcome analysis. Kaplan Meier analysis was performed in 
comparison to survival data from additional 281 glioma patients of 5 reference classes: 82 
PAs WHO grade I, 18 PXAs, 26 anaplastic astrocytomas, IDH mutant (AIII IDH mut), 90 
GBMs, IDH mutant (GBM IDH mut) and 56 GBMs, IDH wildtype (GBM IDH wt).  
Statistical analyses 
The DNA methylation array data were processed with the R/Bioconductor package minfi 
(version 1.20) [2]. For unsupervised hierarchical clustering of histologically defined anaplastic 
pilocytic astrocytomas and reference samples, we selected the 20,000 most variably 
methylated CpG sites across the dataset according to median absolute deviation. Pairwise 
similarity of samples was calculated using Euclidean distance. Clusters were then linked 
according to the Ward’s linkage method. The t-SNE plot was computed via the R package 
Rtsne [28] using the 20,000 most variable CpG sites according to standard deviation, 2,000 
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iterations and a perplexity value of 20. To define the MC AAP, cutoffs for the X and the Y 
values were deduced from the t-SNE plot (Fig 1) as follows: -10 < Y < 10 and -20 < X < 2. 
Survival data of MC AAP and reference group patients were evaluated via Kaplan-Meier 
analysis using the JMP software (SAS Institute, Cary, North Carolina, USA). Outcome 
analyses were calculated from the time point of the first histological diagnosis of anaplastic 
pilocytic astrocytoma. Observation time for the Kaplan-Meier analysis was cut at ten years 
(120 months) for all subgroup analyses due to very small numbers of patients remaining 
under observation beyond this. To verify differences of the survival distributions between the 
respective patient groups, the Log-rank test was applied.  
Results 
A subset of histologically defined anaplastic pilocytic astrocytomas share a common 
DNA methylation profile  
We performed DNA methylation analysis of 102 gliomas with the institutional or differential 
diagnosis of anaplastic pilocytic astrocytoma. Unsupervised t-SNE analysis of their DNA 
methylation profiles against 158 reference cases from 12 different glioma DNA methylation 
classes revealed a DNA methylation cluster comprising 83 of these 102 tumors (81%; Fig 1). 
Subgroups within the main group of 83 tumors did not become apparent in the t-SNE 
analysis. The 19 remaining tumors grouped to (or close to) one of the reference classes. Two 
of these showed high similarity to high-grade glioma reference classes (one to DMG K27 and 
the other to GBM MID), two to the PXA reference class and 15 cases were similar to the low-
grade glioma reference classes comprising PAs and DNETs. The 83 tumors in the cohort of 
histologically defined anaplastic pilocytic astrocytomas, henceforth denominated DNA 
methylation class anaplastic astrocytoma with piloid features (MC AAP), were further 
characterized by integration of clinical and molecular features. Of note, the MC AAP also 
contained two tumors with a H3 K27M mutation. Indeed, these lesions were located near the 
midline (one in the third and lateral ventricle and the other in the cerebellum), but did not 
otherwise show histological features of DMG K27, as both cases had a piloid morphology. 
Notably, the MC AAP showed similarity with the methylation profiles of the DLGNT reference 
class. Furthermore, two PA MID reference cases clustered to the MC AAP. 
In addition, we performed an unsupervised clustering analysis of the same cohort as 
analyzed by t-SNE (Online Resource 5). This analysis revealed a cluster in which 81 tumors 
were congruent with the 83 MC AAP tumors identified by t-SNE, confirming the assignment 
as a separate DNA methylation cluster. Within this methylation cluster, two subclusters A and 
B (Online Resource 5) were putatively identified. There was, however, no high consistency in 
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repeated clustering analyses and no obvious clinical, histological or molecular differences to 
further suggest treating these as two independent subclusters. 
Re-classification of tumors with histologically defined anaplastic pilocytic 
astrocytomas, but divergent DNA methylation profile  
t-SNE and clustering analysis revealed that 19 of the 102 tumors with histological features of 
anaplastic pilocytic astrocytoma displayed a DNA methylation profile that differed from the 
MC AAP (Fig 1 and Online Resource 5). In keeping with our experience with other series 
[52], (Capper, Jones, Sill, Hovestadt et al., Nature 2018, in press), the majority of these 
tumors could be re-classified on the basis of re-evaluation of histology and orthogonal 
molecular findings (immunohistochemistry for BRAF V600E, H3 K27M, copy number profile 
analysis): six tumors were downgraded to PA WHO grade I, one case was re-classified as 
PXA, one as diffuse midline glioma with H3 K27M mutation, one as GBM, IDH wildtype and 
two as low grade gliomas, not elsewhere classified (NEC). The remaining eight cases could 
not be definitely classified. Online Resources 6, 7 and 8 give details and show examples of 
re-classified and non-classifiable cases. 
Clinical characteristics of the MC AAP 
The tumors in the MC AAP (n=83) were preferentially located in the posterior fossa (74%), 
most frequently in the cerebellum (63%). 17% were located supratentorially, two cases (2%) 
had a supra- and infratentorial localization and 5 cases (7%) were located in the spinal 
compartment (Fig 2a). Median patient age at resection was 41.5 years with only 8 out of 76 
tumors (11%) occurring in patients below the age of 20 years (Fig 2b). The distribution of 
male and female patients was balanced (male:female ratio of 1.1; n=83). Of 67 patients with 
available data, 42 patients (63%) presented with primary surgery and without previously 
known lesions, whereas the investigated tumors of 25 patients (37%) originated from a re-
resection (Fig 2c). For 8 of these cases (12%) a low-grade primary tumor was known, 3 
cases (4%) were initially diagnosed with histologically defined anaplastic pilocytic 
astrocytoma and 14 cases (17%) had primary tumors with unknown initial grade. Of the 8 
patients with a reported low-grade precursor tumor, 6 had been historically diagnosed as PA, 
one as oligodendroglioma and one as diffuse astrocytoma. Unfortunately, material of these 
cases was not available for histological or molecular re-evaluation. For the 25 re-resected 
lesions, second surgery was performed within 10 years in 18 cases (72%), whereas time to 
re-surgery was longer than 10 years in four cases (16%) and was unknown for another three 
cases (12%). Median overall survival after the first diagnosis of histologically defined 
anaplastic pilocytic astrocytoma was 23.6 months (n=41/83) with a range from 19 days up to 
10.9 years. Median time to re-surgery was 1.2 years with a range from 66 days up to 28.3 
years. For patients with a low-grade primary tumor, median time to re-surgery was 3.2 years 
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(n=6/8), whereas in patients with a high-grade primary tumor, median time to re-surgery was 
only 0.9 years (n=3/3). For only 5% (4 cases) of the patients in the whole cohort, previous 
brain irradiation was documented. A diagnosis of neurofibromatosis type 1 was clinically 
known in one patient and clinically suspected in a second patient. We further cannot exclude 
that some of the other NF1 mutations identified in the tumor series (see below) may have 
also been present in the germline. Other hereditary tumor predisposition syndromes were not 
documented.  
Histological and immunohistochemical characteristics of MC AAP tumors 
We were able to comprehensively evaluate 74/83 cases of the MC AAP histologically 
including the assessment of growth and infiltration pattern, cellularity, nuclear pleomorphism, 
mitotic count, presence of necrosis, vascular proliferation and presence of eosinophilic 
granular bodies and/or Rosenthal fibers. The remaining 9 tumors were not comprehensively 
evaluable because of limited paraffin material. Results are summarized in Fig 3. Examples 
for histological features of the MC AAP are shown in Fig 4a, 4b and 4c. In our series features 
of cortical dysplasia adjacent to the tumors were not obvious in any of the cases. 
Immunohistochemical analysis included assessment of the glioma markers ATRX, BRAF 
V600E, H3 K27M and IDH1 R132H. In 44% (24/54) of MC AAP lesions nuclear ATRX 
expression was lost in the tumor cells (Fig 4d). BRAF immunohistochemistry revealed only 
one positive case (1/51, 2%). By H3 K27M immunohistochemistry and confirmatory Sanger 
sequencing analysis, one case (1/47, 2%) with a H3 K27M mutation was identified (Online 
Resource 9). For all the remaining cases tested by immunohistochemistry, H3 K27M (Fig 4e) 
and BRAF V600E were negative. IDH1 R132H immunohistochemistry was negative in all 
cases investigated (45/45) (Fig 4f).  
DNA copy number aberrations in the MC AAP - CDKN2A/B deletion represents the 
most frequent structural aberration 
Copy number profile analysis of the MC AAP tumors disclosed numerous, partially complex 
chromosomal alterations: in 73 of 83 cases (88%), more than three structural aberrations 
were found, whereas a small subset of 10 cases (12%) exhibited three or fewer alterations. 
Fig 5a illustrates a representative copy number profile of a PA in the posterior fossa, 
whereas in Fig 5b, an example of a copy number profile for a tumor of the MC AAP is shown. 
Fig 5c and d show a summary plot of chromosomal aberrations of 45 PA reference cases 
(comprising 15 cases of posterior fossa PA, 18 cases of midline PA and 12 cases of 
supratentorial PA) and from all 83 tumors of the MC AAP. The most frequent aberration in 
the MC AAP (66/83 cases, 80%) was a deletion of CDKN2A/B, which was frequently 
associated with broader deletions or complex changes on chromosome arm 9p (41/83 cases, 
49%). A further significant finding was a BRAF fusion indicated by a focal low level peak  
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indicative of a tandem duplication on chromosome 7q in 15 out of 74 assessed cases (20%) 
(Fig 5b, 5d, 6). Other recurrent copy number aberrations were gains and/or complex changes 
on chromosome arms 12q (27%) and 17q (33%) as well as deletions on chromosomes 1p 
(19%), 8p (23%) and 19q (22%). A CDK4 amplification was detected in seven cases (8%) 
and this was associated with a concomitant MDM2 amplification in four cases (5%). Other 
recurrent amplifications more commonly seen in GBM (e.g. of MDM4, PDGFRα, EGFR, 
CDK6, MET) were not observed. 
MC AAP tumors harbor mutations in MAPK pathway genes 
Alterations affecting genes encoding members of the mitogen-activated protein kinase 
(MAPK) pathway have previously been found to occur in up to 100% of WHO grade I PAs 
[21-23]. By combining immunohistochemistry, panel sequencing and copy number analysis, 
we were able to comprehensively examine the status of MAPK pathway gene alterations for 
65 of 83 tumors of the MC AAP (Fig 6). In 49 out of these 65 cases (75%), at least one 
characteristic MAPK pathway gene alteration was detected. In notable contrast to typical 
PAs, the most frequently affected gene was NF1, being altered in 20 of 67 lesions (30%). In 
total, five tumors exhibited a deletion, 10 cases harbored a mutation (including one clinically 
known NF1 syndrome patient) and three cases showed both, a deletion in the copy number 
profile and a mutation of the NF1 gene. The remaining two tumors showed 
immunohistochemical loss of NF1 protein expression and a balanced NF1 gene dosage in 
the copy number profile. Since matching constitutional DNA was unfortunately lacking for 
most cases, we cannot comment on the rate of germline versus somatic NF1 alterations in 
the series. BRAF was the second most frequently altered MAPK pathway gene: 15 of 74 
cases (20%) harbored a BRAF fusion and one case (1%) a BRAF V600E mutation. In 12 out 
of 64 cases (19%) an FGFR1 alteration was detected. Among these, 11 of 64 tumors (17%) 
had a point mutation at one of the known hotspots (K656E/N, N546D/K) and one case (2%) 
exhibited an FGFR1:TACC1 fusion. In another two of 64 cases (3%) a KRAS point mutation 
(Q61H in one and V14A in the other) was detected (Fig 6). MAPK pathway gene alterations 
were mutually exclusive with the exception of one case harboring both an NF1 and an 
FGFR1 alteration (Fig 6). The deFuse software tool was used to identify KIAA1549:BRAF, 
FAM131B:BRAF and FGFR1:TACC1 fusions and to screen for NTRK2 fusions. Other gene 
fusions were not sufficiently covered by our gene panel and were thus not identifiable by our 
approach. RNA sequencing was not performed. 
MC AAP tumors frequently display alterations of ATRX, but rarely of TERT 
Alterations in mechanisms of telomere maintenance are well known drivers of tumor 
progression in a variety of entities. In particular, TERT promoter and ATRX mutations are 
frequently described in diffuse gliomas and have been established as useful markers for their 
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classification and prognostication [37, 41, 42]. Unexpectedly, we found a high rate of ATRX 
alterations in the MC AAP. 74 cases were evaluable for ATRX alterations either by 
immunohistochemical stainings and/or by panel sequencing analysis. From these 74 tumors, 
33 (45%) displayed either a loss of ATRX expression and/or an ATRX mutation. In 15 of 64 
tumors (23%) mutant ATRX was detected by panel sequencing and 24 of 54 tumors (44%) 
showed an immunohistochemical loss of nuclear ATRX expression. For 21 of the latter 24 
cases panel sequencing data were also available: among these, an ATRX mutation was 
confirmed in 12 cases (57%). In the 18 cases with retained nuclear ATRX expression and 
with available panel sequencing data, no ATRX mutation was detected. In summary, an 
ATRX mutation was confirmed in a subset of tumors with immunohistochemical loss of ATRX 
expression by gene panel sequencing. Hence, the sensitivity of our gene panel sequencing 
approach to predict ATRX protein loss was 57%, the specificity being 100%. In a study on 
IDH mutant gliomas, ATRX gene alterations were also not found in a subset of cases with a 
loss of nuclear ATRX expression, suggesting alternative mechanisms of inactivation [58].  
ATRX alterations and TERT promoter mutations are known to occur in a mutually exclusive 
manner in gliomas [25, 42]. To determine the rate of TERT promoter mutations in the MC 
AAP and to explore, whether these are mutually exclusive with ATRX alterations in this newly 
defined tumor class, we performed Sanger sequencing of the TERT promoter region for 74 
tumors of the MC AAP from which 31 cases carried an ATRX alteration (Fig 6). Two tumors 
(3%) with a TERT promoter mutation, both with the nucleotide exchange C228T, were 
identified. Both tumors did not harbor an ATRX alteration. While gain of chromosome 5p was 
observed in approximately 10% of MC AAP tumors, no focal TERT amplifications were seen 
(Fig 5c). 
MGMT promoter hypermethylation is a frequent finding in MC AAP tumors 
In 38 out of 83 tumors of the MC AAP (46%), the MGMT promoter was hypermethylated. 
Another 38 tumors (46%) showed a non-methylated MGMT promoter and in 7 tumors (8%), 
the MGMT promoter methylation status as assessed by array analysis was not determinable 
and MGMT promoter pyrosequencing could not be performed due to lack of material (Fig 6). 
Comparison of the MC AAP with the molecular subtypes of glioma previously 
described by Ceccarelli et al. 
Ceccarelli et al have recently identified a subset of adult diffuse IDH wildtype gliomas within 
The Cancer Genome Atlas (TCGA) data showing a DNA methylation profile distinct from the 
classic-like and mesenchymal-like GBM defined by Sturm et al. [7, 53]. This subset of tumors 
has been shown to be further subdivided into two DNA methylation subclasses, of which one 
shows similarity to GBM and the other to PA. These DNA methylation subclasses have been 
designated “LGm6-GBM” and “PA-like low-grade gliomas” (LGG) [7]. To explore the 
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relatedness of DNA methylation profiles of our MC AAP (n=83) to the PA-like LGG cohort of 
the TCGA series (n=29 tumors of 26 patients), we performed a t-SNE analysis of the two 
series together with the established reference classes (Fig 7). While 5 of 29 PA-like LGG 
clustered more closely to GBM and 14 of 29 clustered more closely to low-grade glioma 
reference classes, the DNA methylation profiles of 10 of these 29 TCGA tumors (7 patients) 
showed high similarity to the MC AAP. Interestingly, the tumors of these 7 patients were also 
enriched for ATRX, but not for BRAF alterations [7]. Among the 5 TCGA tumors which fell 
into the GBM reference classes, one with a H3 G34 and one with a H3 K27 mutation was 
reported [7]. Indeed, these two cases clustered as expected to the GBM G34 and the DMG 
K27 reference methylation class, respectively.  
Outcome analyses  
As this study is a retrospective analysis, availability of clinical data was limited. Outcome 
data were available for 41 of the 83 patients with an MC AAP tumor: by the date of last 
follow-up, 18 patients (44%) had died and 23 patients (56%) were alive. Median overall 
survival was 720 days (23.6 months). Kaplan Meier analysis of these 41 patients against 
outcome data of five glioma reference classes showed a survival probability inferior to 
patients with conventional PA, PXA and IDH mutant anaplastic astrocytoma and comparable 
outcome to patients with IDH mutant GBM, but superior to patients with IDH wildtype GBM 
(Fig 8a). Of note, univariate outcome analysis of patients of the MC AAP with a characteristic 
MAPK pathway gene alteration identified in this study compared to patients for whom such 
an alteration was not detected showed a significantly better prognosis (p=0.032, Fig 8b). 
Kaplan-Meier analysis for the detected individual MAPK pathway gene alterations alone was 
also performed and showed no significant differences of survival probabilities between 
patients with BRAF, NF1 or FGFR1 altered tumors and patients negative for a characteristic 
MAPK pathway gene alteration (Online Resource 10). No significant outcome differences 
were seen in patients with MGMT methylated versus non-methylated tumors (p=0.922) as 
well as in patients with ATRX altered versus ATRX wildtype tumors (p=0.685) (Fig 8c, d). 
Furthermore, outcome analysis dependent on histological criteria (presence/absence of 
necrosis, mitotic count) was performed (n=38). No significant difference in survival probability 
between tumors with versus without necrosis (p=0.468) or with 0, 1-2 versus more than 2 
mitoses (p=0.383) was evident (Online Resource 11). Among the 38 cases with available 
survival data and comprehensive histological review, only two cases showed palisading 
necrosis. Therefore, separate testing for this feature in outcome analysis was not feasible. 
Kaplan Meier analysis was also performed separately for patients with tumors diagnosed 
with histologically defined anaplastic pilocytic astrocytoma on first resection vs. those that 
were diagnosed with histologically defined anaplastic pilocytic astrocytoma on re-resection 
(Online Resource 12). Survival of these two groups did not differ significantly. Due to 
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retrospective inquiry of clinical data for the patient cohort in this study, treatment information 
such as extent of surgery, application of chemotherapy or preoperative performance status 
were not documented in a systematic or standardized fashion. Therefore, a comprehensive 
data set concerning these factors could not be compiled. 
Discussion 
In this study we report a novel class of glial tumors with a common DNA methylation profile 
including many cases with a morphological overlap with PA with anaplasia as described in 
the WHO classification 2016 [29]. However, detailed histological evaluation shows a wide 
range of morphological features that would occasionally be more in line with other tumor 
entities (especially high-grade glioma/GBM). Thus, as with a growing number of CNS tumors, 
the tumor class defined here by DNA methylation profiling (MC AAP) is not exactly congruent 
with PA with anaplasia as defined in the current WHO classification [29]. 
Initially, t-SNE and cluster analysis of the DNA methylation profiles were performed and 
consistently revealed a DNA methylation cluster denominated MC AAP (anaplastic 
astrocytoma with piloid features). The closest resemblance of the DNA methylation profiles of 
these tumors was evident with the reference DNA methylation class of DLGNT (Fig 1, Online 
Resource 5). Indeed, these tumors may be somehow related to PA with anaplasia, since 
they also frequently harbor BRAF fusions, but additionally show other alterations not typically 
found in classical PA (e.g. 1p loss) [6]. In the t-SNE analysis, two cases with H3 K27M 
mutation also clustered to the MC AAP, indicating that this mutation may also occur in these 
tumors. This adds to the notion that H3 K27M mutations are not 100% specific for DMG K27 
but may also occur in other tumors [59]. Further two PA MID reference tumors clustered 
among the MC AAP. This may indicate a certain degree of closer relation of these tumors to 
the MC AAP, but may also be related to technical limitations of t-SNE analyses to classify 
individual tumors. Analysis of a higher number of cases is required to further explore the 
profiles of such histologically low grade lesions clustering to the MC AAP and to identify 
possible subgroups within the MC AAP. 
Our further investigations focused on the clinical, histological and molecular characterization 
of the MC AAP. As also previously reported for a series of histologically defined anaplastic 
pilocytic astrocytomas [44], we observed a higher median patient age in the MC AAP than in 
conventional PAs [5]. In fact, gliomas belonging to the MC AAP mostly arise in adults. Only 
11% (8/76) of these tumors occurred in patients less than 20 years of age. The most frequent 
tumor localization in our series was the posterior fossa (74%) with 63% of the tumors 
originating in the cerebellum. Compared to a previously reported series of histologically 
defined anaplastic pilocytic astrocytomas [44], the posterior fossa localization seems even 
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more frequent among gliomas of the MC AAP. Importantly, clinical history of radiotherapy 
was reported in only 5% (4/83) of the patients. Thus, the role of irradiation in progression 
from conventional PA to anaplasia (and indeed, whether such progression occurs at all as 
opposed to de novo occurrence of an anaplastic lesion) may require additional investigation 
[1, 44]. Another issue of interest was the exploration of differences in the molecular profiles 
between tumors which were primarily anaplastic and tumors reported to develop from lower 
grade lesions (secondarily anaplastic). Differences between these two groups were not 
obvious in this study. We are currently compiling a series of classic PAs that later recurred as 
anaplastic tumors to explore if the initial tumor already harbored specific molecular features. 
As shown in Fig 3, we observed a wide spectrum of histological features in our series:  most 
of the tumors in the MC AAP showed a piloid or GBM-like general morphological pattern, 
were moderately cellular, had moderate nuclear pleomorphism, at least 1 mitosis per 10 HPF 
and microvascular proliferation. Around one third of the tumors exhibited areas of necrosis 
and one third showed eosinophilic granular bodies or Rosenthal fibers, respectively. In 
summary, morphological characteristics of the MC AAP were not particularly specific and 
may overlap with other low and high-grade gliomas. Despite evidence of typical histological 
features of anaplasia in a small subset of tumors, our investigations revealed that the 
histology of the majority of cases in our series appears rather inconspicuous. Thus, in an 
analogous fashion to other tumors such as IDH mutant gliomas, molecular analysis may be 
required in order to come to a final, integrated diagnosis. With regard to 
immunohistochemistry, the most interesting finding was a loss of nuclear ATRX expression in 
a subset of MC AAP tumors. Besides, Ebrahimi et al. previously did not detect ATRX 
alterations in conventional PAs, but identified one case of histologically defined anaplastic 
pilocytic astrocytoma and one case of BRAF-fused cerebellar GBM with loss of ATRX 
expression [10]. Notably, an ATRX mutation was verified in only a major subset of MC AAP 
tumors. As in a previous study on IDH mutant gliomas, an ATRX mutation was not found in 
all cases with lost ATRX expression. It therefore appears likely that other mechanisms 
besides exonic mutations, such as small deletions, may also result in a functional (and 
immunohistochemical) loss of ATRX protein [58]. 
MGMT promoter methylation status has been shown to have predictive and prognostic value, 
particularly for patients with GBM [14, 26, 33]. This study revealed that MGMT promoter 
hypermethylation was present in approximately half of MC AAP tumors, whereas in a control 
cohort of conventional PAs (n=45), the MGMT status was either non-methylated in most of 
the cases (35/45, 78%) or not determinable in a small subset (10/45, 22%) of tumors. These 
data indicate that MGMT promoter methylation status may be of some diagnostic relevance 
in terms of distinguishing conventional PA from AAP. However, the present data do not 
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provide any evidence for an association of MGMT promoter methylation status with OS 
amongst the MC AAP. Admittedly, the prognostic value of this outcome analysis is very 
limited, as clinical information about previous chemotherapy and applied pharmaceuticals 
(e.g. temozolomide) were not available for most of the cases. 
Another important finding of this study was that the distribution of MAPK pathway gene 
alterations in MC AAP clearly differed from that known for conventional PA. In particular, 
BRAF fusions are known to be the most abundant molecular alteration in conventional PAs 
with a frequency of up to 75%, depending on tumor localization and patient age. The second 
most common alteration in approximately 7% of PAs involves the NF1 gene followed by 
activating BRAF mutations (5%) and FGFR1 hotspot mutations (5%). Rarely (about 1 up to 
2% each) NTRK2 fusions, PTPN11 mutations and RAF1 fusions were described [21, 24]. In 
contrast, with a frequency of only 20%, BRAF fusions were surprisingly rare in the MC AAP, 
whereas NF1 turned out to be the most frequently affected gene being altered in 30% of the 
tumors. It was not possible to determine germline NF1 status in most cases. Furthermore, a 
substantial fraction (19%) of tumors harbored an FGFR1 alteration. Among these, in one 
tumor, an FGFR1:TACC1 fusion was detected, as previously reported in pediatric low-grade 
as well as in high-grade gliomas. This aberration has also been shown to transform primary 
astrocytes into highly proliferating glial tumors [49, 59]. NTRK2 fusions and PTPN11 
mutations were not observed and a KRAS mutation was detectable in only two cases (3%). 
FGFR1 alterations have been described to be preferentially found in extra-cerebellar and 
especially in midline gliomas [8, 24]. However, in the present series, the majority of FGFR1 
mutant cases were located in the posterior fossa (Fig 6). Hence, these data indicate that 
FGFR1 alterations may not be restricted to supratentorial midline localizations. BRAF 
alterations have been described to be less frequent (36% of cases) in adult compared to 
juvenile PAs [36]. In a study conducted by Hasselblatt et al., comparable results were 
obtained with a fraction of BRAF fusions of 30% in patients aged 31-40 years and of 7% in 
patients older than 40 years [16]. As MC AAP is also characterized by a higher patient age, 
the age distribution of BRAF fusions may explain the comparably low fraction of tumors 
positive for a BRAF fusion in the present series. By analysis of copy number profiles of 
classical PAs and MC AAP tumors we observed that CDKN2A/B deletion in a BRAF fusion 
positive astrocytic glioma is highly suggestive for the diagnosis of AAP and makes the 
diagnosis of WHO grade I PA highly unlikely. 
Aberrant activation of the MAPK pathway in PA, particularly by BRAF or RAS activation and 
NF1 inactivation, is thought to trigger oncogene-induced senescence (OIS) via engagement 
of the cyclin dependent kinase inhibitors p16Ink4a, the gene product of CDKN2A, and/or 
p21Waf1. As these proteins trigger cell cycle arrest, they are thought to be associated with the 
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indolent biological and clinical behavior of conventional PAs [21]. Rodriguez et al. observed a 
loss of p16Ink4a in a subset of PAs with anaplastic features [43]. Another study revealed that 
PA patients with immunohistochemical loss of p16Ink4a expression had a shorter overall 
survival than PA patients with retained p16Ink4a expression [39]. These findings raised the 
question, whether the prognosis of patients with an MC AAP tumor may be associated with 
the presence or absence of p16Ink4a. Due to the low case number of only 4 patients with a 
balanced CDKN2A/B copy number and available survival data, outcome analysis for this 
parameter could not be performed. Approximately half of the tumors comprising the MC AAP 
displayed a MAPK pathway gene alteration in combination with a CDKN2A/B deletion. For 
these tumors, impairment of OIS may be likely. ATRX has recently been suggested to also 
play a role in oncogene induced senescence:  Kovatcheva et al. showed that ATRX binds to 
oncogene induced senescence-associated gene loci, particularly to the HRAS gene locus, 
and represses their activity. Conversely, high expression of HRAS is supposed to prevent 
senescence induction [27]. Based on these data, it could be hypothesized, that acquisition of 
an ATRX alteration may represent another mechanism of impairing oncogene induced 
senescence in MAPK-altered tumors, and that this may contribute to the adverse biological 
and clinical behavior of AAPs. 
Existence of anaplastic features in PA has previously been found to be associated with 
decreased overall survival. In one series, outcomes of patients with histologically defined 
anaplastic pilocytic astrocytomas were indeed less favorable in comparison to conventional 
PA patients. Survival data were stated as comparable to WHO grade II and III diffusely 
infiltrative astrocytomas, but still better than grade WHO IV GBMs [44]. Another study 
suggested that patients with histologically defined anaplastic pilocytic astrocytomas may 
have a better prognosis than other high-grade gliomas in adult patients [12]. However, 
Kaplan Meier analysis of MC AAP patients in the present series revealed a survival 
probability worse than patients with IDH mutant anaplastic astrocytoma, WHO grade III and 
comparable to patients with IDH mutant GBM, WHO grade IV (although better than patients 
with IDH wildtype GBM, WHO grade IV). Median overall survival of approximately 720 days 
(23.6 months) was consistent with the results of other authors [44]. Notably, the 
comparability of the outcome data discussed above may be limited, as cases for previously 
performed analyses were selected by histological criteria, whereas for the present series, 
molecular data were additionally taken into account and may have led to a higher 
discrimination selectivity against other glioma entities. Another notable finding of this study 
was that patients with tumors, in which a characteristic MAPK pathway gene alteration was 
detected by the applied methods, were found to survive significantly longer than patients with 
tumors carrying no characteristic MAPK pathway gene alteration. The status of MAPK 
pathway genes in the present series was assessed by copy number profile analysis, Sanger 
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sequencing and panel sequencing. Admittedly, these methods do not cover all rare BRAF 
(e.g. RNF130:BRAF, CLCN6:BRAF, MKRN1:BRAF, GNAI1:BRAF etc.) or RAF1 fusions or 
other rarer events. In contrast, Jones et al. detected MAPK pathway gene alterations in 
96/96 PAs when applying RNA and whole-genome sequencing [24]. Therefore, it is possible 
that some of the MC AAP tumors without a characteristic MAPK pathway gene alteration 
rather harbor rare alterations that we were not able to detect using our approach. Hence, 
further analyses, such as RNA and whole-genome sequencing, are required to explore 
possible alternative alterations in the tumors of the MC AAP and, when indicated, to 
reappraise, whether the absence of MAPK pathway gene alterations may indeed be 
associated with a worse outcome.  
For diagnostic practice it is important to appreciate that the tumors allotted to the MC AAP 
show overlapping histological and/or molecular features to PA, pilocytic astrocytoma with 
anaplastic features, PXA and – to some extent – to DMG K27 and to GBM. In particular, 
PXAs frequently harbor alterations of BRAF (typically V600E mutation) combined with loss of 
CDKN2A/B [26, 56] and PAs frequently show a range of MAPK gene alterations [16, 20, 21]. 
Hence, distinction between the above-named entities may become challenging [30]. Fig 9 
provides a suggestion of an algorithm for the diagnosis of AAP. As indicated, 
immunohistochemical and single parameter molecular analysis may at least help to exclude 
other glioma classes. Nonetheless, comprehensive molecular investigations (such as DNA 
methylation profiling and/or gene panel sequencing) may be necessary to definitively confirm 
this diagnosis.  
In conclusion, we demonstrate that MC AAP tumors are characterized by a common DNA 
methylation profile and recurrent alterations of NF1, BRAF or FGFR1 together with 
CDKN2A/B and ATRX loss as well as MGMT promoter hypermethylation. AAP most often 
arises as a primary tumor in the posterior fossa of young to middle-aged adults, although it 
may possibly also develop secondarily in the context of a lower grade tumor. Further 
investigations are required, in particular on the clinical behavior of these rare tumors, as our 
retrospective data is rather fragmented. Nonetheless, our attempt to molecularly characterize 
histologically defined anaplastic pilocytic astrocytomas may provide a basis for establishing 
the position of the MC AAP in brain tumor classifications and may – at some stage – enable 
a refinement of stratification of patients for clinical trials. 
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